



APP/A β structural diversity and Alzheimer's disease pathogenesis



Alex E. Roher^{a, b, *}, Tyler A. Kokjohn^c, Steven G. Clarke^d, Michael R. Sierks^e,
Chera L. Maarouf^f, Geidy E. Serrano^f, Marwan S. Sabbagh^g, Thomas G. Beach^f

^a Division of Neurobiology, Barrow Neurological Institute, Phoenix, AZ 85013, USA

^b Division of Clinical Education, Midwestern University, Glendale, AZ 85308, USA

^c Department of Microbiology, Midwestern University, Glendale, AZ 85308, USA

^d Department of Chemistry and Biochemistry and the Molecular Biology Institute, University of California, Los Angeles, Los Angeles CA 90095-1569, USA

^e Department of Chemical Engineering, Arizona State University, Tempe, AZ 85287-6106, USA

^f Laboratory of Neuropathology, Banner Sun Health Research Institute, Sun City, AZ 85351, USA

^g Alzheimer's and Memory Disorders Division, Barrow Neurological Institute, Phoenix, AZ 85013, USA

ARTICLE INFO

Article history:

Received 31 May 2017

Received in revised form

25 July 2017

Accepted 11 August 2017

Available online 12 August 2017

ABSTRACT

The amyloid cascade hypothesis of Alzheimer's disease (AD) proposes amyloid- β (A β) is a chief pathological element of dementia. AD therapies have targeted monomeric and oligomeric A β 1–40 and 1–42 peptides. However, alternative APP proteolytic processing produces a complex roster of A β species. In addition, A β peptides are subject to extensive posttranslational modification (PTM). We propose that amplified production of some APP/A β species, perhaps exacerbated by differential gene expression and reduced peptide degradation, creates a diverse spectrum of modified species which disrupt brain homeostasis and accelerate AD neurodegeneration. We surveyed the literature to catalog A β PTM including species with isoAsp at positions 7 and 23 which may phenocopy the Tottori and Iowa A β mutations that result in early onset AD. We speculate that accumulation of these alterations induce changes in secondary and tertiary structure of A β that favor increased toxicity, and seeding and propagation in sporadic AD. Additionally, amyloid- β peptides with a pyroglutamate modification at position 3 and oxidation of Met35 make up a substantial portion of sporadic AD amyloid deposits. The intrinsic physical properties of these species, including resistance to degradation, an enhanced aggregation rate, increased neurotoxicity, and association with behavioral deficits, suggest their emergence is linked to dementia. The generation of specific 3D-molecular conformations of A β impart unique biophysical properties and a capacity to seed the prion-like global transmission of amyloid through the brain. The accumulation of rogue A β ultimately contributes to the destruction of vascular walls, neurons and glial cells culminating in dementia. A systematic examination of A β PTM and the analysis of the toxicity that they induced may help create essential biomarkers to more precisely stage AD pathology, design countermeasures and gauge the impacts of interventions.

© 2017 Elsevier Ltd. All rights reserved.

Contents

1. Introduction	2
2. Amyloid- β posttranslational modifications and AD pathophysiology	2
2.1. Aspartyl isomerization	3
2.2. Pyroglutamate modification	4
2.3. Phosphorylation	4
2.4. Oxidation	4
2.5. Nitrosylation	4
3. The intriguing role of dimeric A β in AD pathology	4

* Corresponding Author. Division of Neurobiology, Barrow Neurological Institute, Phoenix, AZ 85013, USA.

E-mail address: aeroher@gmail.com (A.E. Roher).

4.	The role of soluble oligomeric A β peptides	5
5.	The complicated catalog of APP/A β -related peptides and AD amyloidosis	5
6.	Implications of the AN-1792 active vaccination clinical trial	6
7.	Peripheral A β	6
8.	Future biomarker discovery and immunotherapy tactics	7
9.	Conclusions	7
	Competing interests	8
	Acknowledgements	8
	References	8

1. Introduction

Alzheimer's disease (AD) is characterized by the deposition of amyloid plaques and neurofibrillary tangles (NFT) in the brain. The main component of extracellular amyloid plaques is the amyloid- β peptide (A β), an approximately 4 kDa fragment derived from the larger amyloid precursor protein (APP) by the concerted action of β - and γ -secretases (Masters and Selkoe, 2012). The A β peptides polymerize into insoluble ~10 nm filaments which accumulate in senile plaques and the walls of cerebral blood vessels. The NFT are aberrant aggregates mainly composed of tau, a phosphorylated microtubule-associated protein that aggregates into insoluble intraneuronal paired helical filaments (Goedert et al., 1992). While recognizing the importance of NFT as potential co-pathogenic species in AD, in this critical review we focus specifically on the role of A β .

The evolutionary conservation of A β suggests this molecule has an adaptive value and important function(s) in the maintenance of CNS homeostasis. Of all 30 mammalian orders, which began to diverge about 90 million years ago, rodents are the only known species harboring amino acid substitutions deviating from the ancestral A β sequence. In sharp contrast with humans and many other mammals, age-associated amyloid deposits do not accumulate in rodents (with the exception of the brush tailed rat) *in vivo* (Shivers et al., 1988; Roychaudhuri et al., 2015), even though synthetic rodent A β peptides produce congophilic filaments *in vitro* (Fung et al., 2004; Hilbich et al., 1991). Animal and cellular models are necessary for ascertaining disease mechanisms and promoting drug discovery efforts. However, there are still considerable challenges in translating scientific findings from these models into effective clinical interventions.

The amyloid cascade hypothesis is currently the most widely accepted general theory to explain the pathophysiology and clinical evolution of AD. The hypothesis posits A β 40 and A β 42 peptides are the critical elements in AD pathogenesis, through their intra- or extracellular neuropil and vascular accumulation. Notwithstanding the genetic evidence suggesting a crucial role for A β , considerable controversy still exists over the precise role(s) of amyloid in AD pathogenesis and pathophysiology (Herrup, 2015; Lee et al., 2006a; Mullane and Williams, 2013). Amyloid plaques correlate weakly with the clinical progression of AD and are preceded by tau neurodegeneration and brain atrophy in limbic brain regions (Chetelat, 2013; Jack et al., 2016a; Josephs et al., 2008; Prohovnik et al., 2006; Villemagne et al., 2011; Wolk, 2013; Boyle et al., 2013; Nelson et al., 2010, 2012a, 2012b). To account for discrepancies between amyloid deposition and AD dementia some investigators suggest that soluble oligomeric A β are the most toxic species. The literature pertaining to the role of oligomeric A β in the pathogenesis and pathophysiology of AD is extensive (Selkoe and Hardy, 2016; Tu et al., 2014; Watson et al., 2005; Williams and Serpell, 2011) with almost 5000 articles listed under "oligomeric A-beta" in PubMed. Excellent reviews on these topics can be found in references

(Masters and Selkoe, 2012; Watson et al., 2005). However, no consensus exists regarding the molecular form(s) of A β ultimately responsible for the neurological decline associated with AD, the form(s) which should be therapeutically targeted or the optimal time to commence treatment. The timing of the initial A β accumulation and its propagation during the course of disease remains controversial (LaFerla et al., 2007). Likewise, whether A β accumulation in the CNS is influenced by A β pools originating from peripheral tissues and/or the systemic circulation is unclear (Carnevale et al., 2012; Deane et al., 2003; Eisele et al., 2014; Mackic et al., 2002).

The hallmark of AD amyloid found in demented subjects is its immense complexity. Commonly presumed to be composed of A β 40 and A β 42 species, extensive posttranslational modifications (PTM) produce a wide array of molecules differing in physical size and chemical/conformation properties. Analogous to the situation observed with other proteinopathies, some of these potentially toxic modified A β conformers may promote the proliferation of highly organized amyloid filaments (Jucker and Walker, 2013; Prusiner, 2012, 2013).

We hypothesize that in late onset AD (LOAD), specific A β -related species with shorter or longer sequences and/or altered by PTM enhance noxious amyloid deposition and neurotoxicity. Based on these assumptions, we review experimental evidence revealing the physicochemical nature of potentially neurotoxic amyloid species linked to AD. We consider neglected factors such as covalent modifications of A β and its aggregation states that may influence AD pathophysiology and have important implications for the design of immunotherapies. We consider APP proteolysis fragments and peripheral A β sources as potential factors influencing neurodegeneration and cognitive dysfunction. In addition, we propose tactics to aid the search for prospective A β biomarkers and therapeutic targets.

2. Amyloid- β posttranslational modifications and AD pathophysiology

Structural alterations in the peptide backbone of A β could account for the differential deposition and stability of these molecules in AD (Roher et al., 1993a). Detailed analyses have revealed that the species present in AD brains are modified extensively (Kummer and Heneka, 2014). Furthermore, the A β peptides isolated from amyloid plaque cores possess a heterogeneous array of N- and C-termini and variable quantities of water soluble and water insoluble A β (Roher et al., 1993a; McDonald et al., 2012). The fundamental chemical characteristics of the A β polypeptides are dictated by the amphipathic nature of these molecules, the presence of non-polar and polar domains and an abundance of charged amino acid residues which impose a diverse array of secondary and tertiary structures. Amyloid- β peptides ending in residues 38 to 49, a part of the transmembrane domain of the APP molecule, are progressively more hydrophobic due to the enrichment of non-

polar amino acids which decrease solubility and increase aggregation propensity. The removal of charged amino acid residues at the N-terminal region of A β by aminopeptidases, endopeptidases or modification by glutaminyl cyclase will also have critical consequences for the intermolecular ionic interactions of the A β peptides since this region contains Asp and Glu at positions 1, 3, 7 and 11, and Arg, Lys and His at positions 5, 6, 13, 14 and 16. Deletions or additions in the A β sequence will result in differences in molecular folding patterns and intermolecular reactivity. The central domain of A β from Leu17 to Lys28 also contains a conserved hydrophobic domain (Leu17-Val18-Phe19-Phe20-Ala21) and the negatively charged residues Glu22 and Asp23. In the following section we give an account of the most important PTM present in the A β peptides.

2.1. Aspartyl isomerization

Aspartic acid and asparagine residues are particularly subject to non-enzymatic modification reactions that covalently alter the structure of the polypeptide chain. The proximity of the side chain carbonyl group of Asp/Asn to the adjacent residue amide nitrogen induces the formation of a five-membered succinimide ring intermediate (Geiger and Clarke, 1987) which is subject to enhanced racemization (Radkiewicz et al., 1996). Spontaneous hydrolysis of the L- and D-succinimide intermediates generate a mixture of L- and D-aspartyl and L- and D-isoaspartyl residues (Geiger and Clarke, 1987). The presence of the isoaspartyl residue distorts the peptide chain to give a kinked polypeptide conformation that resembles a C-terminal substituted Asn residue. Racemization may also occur via radical reactions (Tambo et al., 2013). L-isoaspartyl residues (and to a lesser extent D-aspartyl residues) can be recognized intracellularly by the protein L-Isoaspartyl (D-aspartyl) O-methyltransferase (PIMT) which initiates their conversion to L-aspartyl and D-isoaspartyl residues (Lowenson and Clarke, 1991). Tryptic digestion and reverse-phase HPLC separation of AD A β peptides yielded several isoforms comprising residues A β 1–5 and A β 6–16 (Roher et al., 1993a). Amino acid composition, amino acid sequence analysis, mass spectrometry, enzymatic methylation and stereoisomer determinations demonstrated structural rearrangements of Asp residues at positions A β 1 and A β 7. L-isoAsp was the predominant form with D-isoAsp, L-Asp and D-Asp present as minor components, as would be expected for succinimide-mediated degradation. Approximately 75% of the A β peptides in the AD brain parenchymal amyloid plaque cores contain isoAsp at position A β 7 with the amount of isoAsp at position A β 1 more difficult to estimate due to the variable degree of N-terminal degradation. A third A β isoAsp site at position 23 has been reported to accelerate the *in vitro* aggregation kinetics of synthetic A β 1–42 (Fukuda et al., 1999; Shimizu et al., 2000, 2005). Interestingly, the A β mutation at position 23 Asp→Asn (Iowa) produces heavy vascular amyloidosis associated with dementia and intracerebral hemorrhages. In this form of familial AD, an isoAsp at position 23 is produced by deamidation of the mutant Asn residue to Asp followed by isomerization, again via a succinimide intermediate (Fossati et al., 2013; Shin et al., 2003; Tomidokoro et al., 2010). The structural resemblance of isoAsp and Asn residues described above may provide some insight into the pathology associated with the A β 23 Iowa mutation. Another A β mutation reported at position A β 7 Asp→Asn (Tottori) alters the conformational dynamics of A β , accelerates the rate of oligomerization and affects metal interactions (Alies et al., 2011; Hori et al., 2007; Ono et al., 2010; Viet et al., 2013).

While immunohistochemical studies suggest that the isoAsp at position 23 is mainly associated with the vascular amyloid deposits, the isoAsp at position 7 appears to be abundant in both parenchymal plaque and vascular related amyloid (Shin et al., 2003;

Tomidokoro et al., 2010; Roher et al., 1993b). These studies also confirmed that in AD subjects the Asp residues at position 1, 7 and 23 are partially isomerized. The preferential localization of isoAsp at position 23 in vascular deposits of A β suggests the isomerization event occurs prior to its vascular deposition, soon after A β formation. Alternatively, the physicochemical conditions in the vascular compartment may favor the isoAsp23 modification. Conversion of Asp23 to isoAsp alter the kinetics of polymerization and may promote propagation of amyloid in the AD brain (Fossati et al., 2013). Recent cryo-electron microscopy (cryo-EM) observations permitted the 3D-structural reconstruction of the A β 42 amyloid filaments (Schmidt et al., 2015). The model predicts that the negatively charged C β carboxyl group of Asp23 hinders a more advantageous packing in the stacking of A β 42 dimer interfaces. Decreasing electrostatic repulsion between adjacent Asp residues will result in a more stable filamentous structure. The formation of IsoAsp may mimic the Asn23 Iowa mutation by displacing the C β side chain carboxylate to the 23C α .

We propose that A β isoAsp at positions 7 and 23 in the AD brain may induce conformational changes analogous to the Tottori and Iowa A β mutations which are localized at the same positions of the A β peptide and associated with early onset AD. These alterations cause changes in secondary and tertiary structure of the A β that may facilitate toxicity, seeding and propagation, perhaps by serving as templates converting unmodified A β species into self-transmissible amyloid species *in vitro*. It has been reported that reversion of isoAsp into Asp occurs in A β in the presence of PIMT and the methyl donor S-adenosyl methionine, resulting in the partial blockade of A β fibrillogenesis (Jung et al., 2011). IsoAsp PTM are undetectable by routine mass spectrometry, since the A β peptides with IsoAsp alterations have an atomic mass identical to native A β -containing Asp residues. However, estimation of isoAsp can be performed by the enzymatic methods published by Dai et al. (Dai et al., 2013) or by electron capture dissociation combined with Fourier transform mass spectrometry (Yang et al., 2009). In addition, using a combination of HPLC and mass spectrometry, it is possible to simultaneously determine both racemization and isomerization in A β (Inoue et al., 2014). The conformational changes induced by A β PTM, alone or in combination, could also mimic the stereochemical disturbances elicited by known deleterious familial AD amino acid substitutions such as Ala21→Gly (Flemish), Glu22→Gln (Dutch), Glu22→Gly (Artic), Glu22→Lys (Italian), in addition to the Asp23→Asn (Iowa) and Asp7→Asn (Tottori), mutations described above. The transition of the peptide bonds from C α -C α to C β -C α carbons, drastically reorients the carboxylate and amino groups which alters the conformation of A β peptides and their isoelectric points. This facilitates the generation of β -pleated sheets (Fabian et al., 1994; Orpiszewski and Benson, 1999; Szendrei et al., 1994, 1996) thereby rendering these molecules more stable and resistant to enzymatic degradation (Bohme et al., 2008; Kuo et al., 1998). Interestingly, while the isoAsp at position A β 1 blocks BACE-1 β -secretase hydrolysis, cathepsin B activity efficiently hydrolyzes peptides with isoAsp at this position (Bohme et al., 2008). Additionally, it has been reported that a membrane bound β -secretase can cleave in the presence of a D-Asp residue (Lee et al., 2002). IsoAsp modifications disrupt the ordered assembly of the α -helix by affecting the stability of the intra- and inter-molecular interactions such as hydrogen bonding, salt bridges and hydrophobic interactions, in turn accelerating rates of A β oligomerization and fibril formation (Fossati et al., 2013; Tomidokoro et al., 2010; Ono et al., 2010; Kuo et al., 1998). These observations strengthen the contention that A β isoAsp isomerization is a potential triggering mechanism for AD amyloidosis and A β neurotoxicity.

2.2. Pyroglutamate modification

Amyloid- β species containing pyroglutamate at position 3 (A β 3pE) have been identified in parenchymal plaques, vascular deposits (Iwatsubo et al., 1996; Mori et al., 1992), presynaptic sites (Mandler et al., 2012) and lysosomes (De Kimpe et al., 2013). About 50% of the A β peptides present in purified amyloid plaque cores and about 11% of the total A β mass in isolated vascular amyloid deposits have N-terminal A β 3pE (Kuo et al., 1997). The formation of A β 3pE requires the removal of the first two N-terminal A β amino acid residues followed by the action of the enzyme glutaminyl cyclase (Perez-Garmendia and Gevorkian, 2013). Numerous investigations have revealed the presence of this peptide in A β deposits, its intrinsic physical properties such as resistance to degradation, fast aggregation rate, increased neurotoxicity, association with behavioral deficits, capacity to form hybrids with other A β species as well as its potential role in AD pathogenesis (Perez-Garmendia and Gevorkian, 2013; D'Arrigo et al., 2009; Gunn et al., 2010; Harigaya et al., 2000; He and Barrow, 1999; Hosoda et al., 1998; Jawhar et al., 2011, 2012; Miravalle et al., 2005; Naslund et al., 1996; Nussbaum et al., 2012; Pike et al., 1995; Portelius et al., 2010; Russo et al., 1997, 2002; Saido et al., 1995; Schilling et al., 2006; Sergeant et al., 2003; Sun et al., 2012; Tekirian et al., 1998; Wirths et al., 2010; Youssef et al., 2008). Antibodies against the A β 3pE modified peptide tested in transgenic (Tg) mouse models decreased A β deposits, inhibited A β aggregation and reduced behavioral dysfunction (DeMattos et al., 2012; Frost et al., 2012; Venkataramani et al., 2012). It has been proposed that the A β 3pE peptide could be a potential seeding template of highly neurotoxic A β (He and Barrow, 1999; Schilling et al., 2006; Schlenzig et al., 2012). Of the many A β PTM, only one, A β 3pE, has been targeted by immunotherapy and is currently in phase-1 clinical testing by Eli Lilly. Unfortunately, this antibody apparently evoked an undesirable immunogenic response in immunized individuals (see: Fagan T. Alzforum News, AAIC-Toronto, 2016; August 24, 2016).

2.3. Phosphorylation

Phosphorylation of A β at Ser8 by protein kinase A (Kumar et al., 2011, 2013) enhances aggregation and toxicity. Phosphorylation of A β at Ser26 by human cyclin-dependent kinase-1 has also been reported to increase A β toxicity (Milton, 2001, 2005). It is possible that Ser phosphorylation has been overlooked because the often employed solubilization process utilizes formic acid which readily hydrolyzes esterified phosphate groups. In addition, several studies have suggested that in the AD brain A β L-Ser26 can be converted to D-Ser. This racemization apparently produces toxic A β fragments that may play a role in neurodegeneration (Kaneko et al., 2001; Kubo et al., 2002, 2003).

2.4. Oxidation

Oxidation of A β at Met35 to sulfoxide (S=O) and sulfone (O=S=O) forms has been the object of intense examination. In AD and mild cognitive impairment, oxidative stress mediated by free radicals instigate protein oxidation, lipid peroxidation and reactive oxygen species (ROS) production conducive to synaptic damage with neuronal and glial demise (Butterfield and Kanski, 2002). Met35 appears to regulate copper-catalyzed oxidation and aid in the generation of noxious hydrogen peroxide (Ali et al., 2005). Electron spin resonance studies have confirmed that Met35 intervenes in free radical production. Substitution of Met35 with Val or Leu residues eliminates free radical production, oxidative stress and hippocampal toxicity of A β (Butterfield and Kanski, 2002; Butterfield et al., 2010; Varadarajan et al., 1999). Furthermore,

induction of Met-sulfoxide reductase in Tg mouse models protected neurons from A β toxicity (Moskovitz et al., 2011). Circular dichroism, thioflavine-T and atomic force microscopy methods indicated that A β Met35-sulfoxide impedes fibril formation (Hou et al., 2002, 2013; Narayanan et al., 2006). Apparently, the presence of oxidized Met35 favors monomers and dimers over larger oligomers and enhances neurotoxicity (Johansson et al., 2007). Molecular dynamics simulations of A β suggest that Met35 oxidation decreases the β -strand content of the C-terminal hydrophobic domain of A β , specifically at the A β 33–35 structural domain and that this configuration hinders A β polymerization (Brown et al., 2014).

2.5. Nitrosylation

Nitration at Tyr10 accelerates A β aggregation and has been detected in the amyloid plaques of both APP/PS1 mice and AD brains (Kummer et al., 2011). In a more recent study A β Tyr10 was found to significantly decrease A β aggregation and cytotoxicity (Zhao et al., 2015).

3. The intriguing role of dimeric A β in AD pathology

In the 1990s the hypothetical cause of AD pathogenesis shifted from the insoluble fibrillar amyloid plaques to soluble oligomeric forms of A β . Substantial work has been dedicated to understanding the physicochemical properties of A β aggregates ranging from dimers to large conglomerates (Harigaya et al., 1995; Kuo et al., 1996; Roher et al., 1996; Tabaton et al., 1994; Teller et al., 1996). In 1996, our group isolated detergent-free, water-soluble A β (n-40 and n-42) from normal and AD brains (Kuo et al., 1996) in which the most prevalent and stable fraction was dimeric A β (Roher et al., 1996). Amyloid- β dimers derived from AD amyloid plaques and vascular deposits were tested for toxicity in cultures of rat hippocampal neurons and glial cells (Roher et al., 1996). Intriguingly, A β dimers elicited neuronal killing only in the presence of microglia. Amyloid- β dimers with PTM, including isoAsp1 and isoAsp7, cyclization of Glu3 to pyroglutamyl and oxidation of Met35, exhibit increased insolubility and stability. Amyloid- β 1–42, with IsoAsp at positions 1 and 7, demonstrated the fastest rate of oligomerization, followed by A β 3pE-42 and A β 1–42. Amyloid- β 1–40 showed a slower dimerization rate while A β 1–28 did not dimerize (Kuo et al., 1998). Furthermore, tryptic digestion resistance progressively increases from A β 1–40 monomer, A β 1–42 monomer, A β 3pE-42 monomer, A β 1–42 (1,7 isoAsp) monomer, A β 1–42 (1,7 isoAsp) dimer and A β 17–42. Amyloid- β 1–42 with oxidized Met35 to either Met sulfone or sulfoxide, was ~50% more resistant to digestion than non-oxidized A β 1–42 (Kuo et al., 1998). These experiments suggest that the length of the A β peptides and PTM induce structural changes which impart unique physicochemical properties and functional effects.

Several dimeric and oligomeric A β models have been investigated in recent years (reviewed in reference (Masters and Selkoe, 2012)). Dimeric A β based on FASTA and BLAST SwissProt data using the PredictProtein and TOPITS algorithms yielded a Greek-key A β motif conformation in which four antiparallel β -strands generate a compact A β dimer with a hydrophobic core to shelter non-polar residues from the surrounding water (Chaney et al., 1998). In this model, the hydrophobic C-terminal domains of the A β dimer are thermodynamically shielded since they are partially buried along the dimer crevices, but can be extended to form the core of antiparallel β -sheets (see below). This model was further refined by molecular dynamics simulations (Chaney et al., 1998). Atomic force microscopy of purified dimers from amyloid plaques revealed the A β dimer as a compact globular hydrated structure ~35–38 Å in diameter (Roher et al., 1996; Chaney et al., 1998). A series of studies suggests the importance of the stable soluble A β

oligomers in AD cognitive dysfunction (Chaney et al., 1998; Garzon-Rodriguez et al., 1997; Kaye et al., 2003; Kokubo et al., 2005), conformational-dependent mechanisms of neurotoxicity (Deshpande et al., 2006), ability to induce tau hyperphosphorylation and neuronal degeneration (Jin et al., 2011) as well as stability in SDS solutions (McDonald et al., 2012) with the latter property implicated in the generation of concentration-dependent dimers (Watt et al., 2013). However, dimers have been purified in our laboratory in the absence of detergents (Kuo et al., 1996). Amyloid- β dimers isolated from the human brain impair synaptic plasticity and are detrimental to memory by inhibiting long-term potentiation, enhancing long-term depression and decreasing dendritic spine density in animal models (Shankar et al., 2008). Moreover, the degree of neurotoxicity is apparently dependent on the amount of A β dimers/trimers (Hung et al., 2008). Recent experiments suggest that the binding of interstitial fluid A β oligomers to GM1 gangliosides produces destabilizing structural changes in membranes (Hong et al., 2014). Synthetic dimeric A β inhibits mitochondrial cytochrome C-oxidase in the presence of copper (Crouch et al., 2005). Single-molecule atomic force microscopy experiments indicate that aggregation of A β is modulated by local environmental conditions and that A β 42 dimerization is an extremely rapid process. In addition, the drastic structural differences between A β 40 and A β 42 may play a key role in dimerization propensity (Kim et al., 2011; Lv et al., 2013). Amyloid- β dimers have also been proposed as the molecular unit in the polymerization of amyloid fibrils. In this model based on cryo-EM, two opposing monomeric A β molecules comprising A β residues 25–41 generate a face-to-face antiparallel β -sheet by adopting an S-shape zipper-like hydrophobic core ‘C-domain’ while leaving the N-terminal regions, mostly composed of polar amino acids (residues 1–24), to make two opposing ‘P-domains’. The subsequent stacking of these dimeric structures creates coiled two-stranded amyloid filaments (Schmidt et al., 2015). It has been estimated that A β dimers are a million-fold more thermodynamically stable than disordered unstructured A β monomers (Kim et al., 2011).

4. The role of soluble oligomeric A β peptides

In recent years oligomers have been assumed to be the ultimate cause for synaptic dysfunction, neuroinflammation, neurovascular compromise and neuronal/glia degeneration, making them the target of intense research and immunotherapy interventions (Selkoe and Hardy, 2016; Watson et al., 2005; Bezprozvanny and Mattson, 2008; Fandrich, 2012; Larson and Lesne, 2012; Palop and Mucke, 2010; Reddy, 2009; Yang et al., 2010). However, the notion of soluble oligomeric A β toxicity still deserves further scrutiny and comprehensive validation. One major problem is that the enormous diversity of the A β peptides influenced by PTM and peptide length also affects the size, biochemistry and biophysical properties of oligomers. Although A β dimers appear to be stable, larger A β oligomers have been isolated from mice and human brains using a variety of purification techniques. Oligomers might assume a very large number of conformational structures with a correspondingly huge diversity of epitopes. This complexity may explain why immunotherapies with antibodies assumed to be reacting with oligomers in the human brain have yielded poor results in clinical trials (reviewed in ref: (Sengupta et al., 2016)). There is no doubt that variable amounts of soluble monomeric and oligomeric A β exist in the human brain because metastable monomeric A β is continuously generated from APP by the action of secretases. There is also proof that, at least under controlled experimental conditions, oligomers are neurotoxic in cell culture and experimental animals (Balducci and Forloni, 2014; Brouillette, 2014; Klein, 2013; Mucke and Selkoe, 2012; Selkoe, 2008; Wisniewski

and Sigurdsson, 2010). However, the definition of A β oligomers is vague since different laboratories in academia and commercial settings produce their own unique varieties based on synthetic peptides and *in vitro* aggregation conditions. In most instances these oligomers, primarily built on unmodified full-length synthetic A β 40 or A β 42 amino acid sequences, have been assumed to be a faithful representation of what is present in the far more complex AD brain environment. In addition, A β oligomers have been extracted from animal or human brains using techniques that employ a diversity of mechanical homogenizing stresses. These extracted species may include artifacts from dispersed fibrillar A β which may not be present in the AD brain.

5. The complicated catalog of APP/A β -related peptides and AD amyloidosis

The profusion of amyloid plaques and their multiple morphological presentations suggests an underlying complexity in chemical compositions. A substantial mass of the amyloid plaque core is composed of a complex mixture of glycoproteins, glycolipids, lipids and proteins other than APP/A β (Kiskis et al., 2015; Liao et al., 2004). Among the best characterized molecules are a variety of glycosaminoglycans, gangliosides, cholesterol, fatty acids, triglycerides, α 1-antichymotrypsin and apolipoprotein E (Abraham et al., 1988; Abraham, 2001; Hughes et al., 2014; Liao et al., 2015; Mori et al., 2001; Mufson et al., 1994; Stewart et al., 2016; Xu et al., 2008; Yanagisawa, 2011) and a large number of proteins identified by mass spectrometry (Liao et al., 2004; Hadley et al., 2015). Approximately 35% of the mass of AD amyloid cores is composed of non-A β molecules (Roher et al., 1993a) enmeshed within an array of 10 nm fibrillar A β peptides. The biological function of the non-A β molecules in the context of plaque pathology and dementia has never been investigated in detail. Based on the conventional notion that in AD amyloid plaques are mainly composed of unmodified A β 1–40 and A β 1–42 peptides, several therapeutic antibodies have been synthesized against short consecutive amino acid sequences of the intact N-terminal, C-terminal and middle domains of these peptides. Biochemical analyses of AD purified amyloid plaque cores have shown that the N-termini of A β are highly variable, probably resulting from aminopeptidase activity that is associated with degradation pathways of A β . In addition, BACE1, that normally cleaves APP to generate the amino terminus of A β 1–40/42, can also cleave APP at residue A β 11 to generate A β 11–40/42 (Kimura et al., 2016). The proteolytic activity of the α -secretase on APP produces the “non-amyloidogenic” A β 17–40/42, recognized as P3, which is abundant in diffuse amyloid plaques in cortical and cerebellar deposits (Gowing et al., 1994; Higgins et al., 1996; Lalowski et al., 1996). These plaques have been deemed “non-fibrillar” but are known from thioflavine-S staining and EM studies to contain a low density of amyloid fibrils (Yamaguchi et al., 1989). Due to its overall hydrophobic composition and insolubility P3 is very difficult to test in cell and animal models leaving the function of this peptide still unknown. However, because it is associated with diffuse plaques and may not elicit adjacent inflammatory reactions, P3 has been assumed to be an innocuous molecule. The potential ability of P3 to disrupt membrane lipids and form ionic channels implies this peptide may induce pathological changes in membrane permeability (Jang et al., 2010, 2013; Yu et al., 2013).

The A β C-termini are also variable (Xu, 2009). It has been proposed that the γ -secretase primarily cleaves APP at residues A β 48 and A β 49, known as ϵ -sites, producing A β 1–48 and A β 1–49, and corresponding intracellular domains (AICD) 49–99 and 50–99 (Qi-Takahara et al., 2005; Takami et al., 2009). In addition, the γ -secretase can hydrolyze APP at residues A β 46–47, the ζ -site (Zhao et al.,

2004), thus generating longer A β peptides (Hartmann et al., 1997; Selkoe and Wolfe, 2007; Wolfe, 2007). The sequential hydrolysis of APP by γ -secretase in AD apparently generates a step-wise series of A β peptides terminating in residues 49, 48, 46, 45, 43, 42, 40, 39, 38 and 37 (Qi-Takahara et al., 2005; Takami et al., 2009). These A β forms have not been quantified in the AD brain. It is likely that the ratios of these A β peptides will vary from individual to individual. Interestingly, in the *PSEN1* EOAD mutation E280A (paisa) the A β C-termini are also heterogeneous with peptides ending at every position from residue 42 to residue 55 (Van Vickle et al., 2008).

The traditional view that concerted processing of APP by the α , β and γ secretases produces A β amyloidogenic and non-amyloidogenic peptides is complicated by the recognition of alternative APP cleavage sites (Andrew et al., 2016). Some elongated A β -related peptides have been isolated and rigorously characterized by amino acid sequencing. Amyloid precursor protein hydrolysis at the δ -position Thr584 (APP₆₉₅) yields a product with an additional 12 amino acid residues extending from the N-terminus of the A β peptide (Simons et al., 1996). More recently, two additional APP/A β peptides produced by an asparagine endopeptidase have been identified. Cleavage of APP₆₉₅ at Asn373 creates an APP N-terminal neurotoxic peptide, and at Asn585 yields an APP C-terminal peptide, composed of residues 586–695 that serves as a preferred substrate for BACE1 (Zhang et al., 2015). It was further suggested that this latter peptide increases amyloid production, highlighting the potential importance of the δ -site in AD pathogenesis (Zhang et al., 2015). Another APP hydrolysis site, defined as the η -site, was discovered between residues 504–505 (APP₆₉₅). The η -peptide is further processed by the β - and α -secretases to create the A η - β and A η - α APP fragments. The latter peptide inhibited neuronal activity in the hippocampus by lowering long-term potentiation (Willem et al., 2015). It has been suggested that cathepsin-L degrades the η -C-terminal fragment of APP (Wang et al., 2015). In addition to these APP-derived peptides, the APP C-terminal fragment containing the last 100 amino acids of APP (emulating β -secretase hydrolysis and absence of γ -secretase cleavage) induces neurodegeneration in transgenic mice (Berger-Sweeney et al., 1999; Oster-Granite et al., 1996). Moreover, the AICD fragment can be further hydrolyzed to yield the Jcasp and the C31 peptides that have been found to induce apoptosis and have neurotoxic activity (Bertrand et al., 2001; Lu et al., 2000; Madeira et al., 2005; Park et al., 2009). Lastly, APP-derived peptide carrying the N-terminal sequence of amino acid residues 18–286 was found to produce axonal pruning and neuronal death by interacting with the death receptor-6 (DR6) via the activation of caspases (Nikolaev et al., 2009).

The evolutionary conservation of the APP and the redundancy generated by the amyloid precursor like-proteins (APLP1 and APLP2A) molecules is a testimony to its importance in modulating the function and fate of cells. The increased expression of APP is likely to generate an overproduction of specific peptides that may influence AD pathogenesis and development (Mattsson et al., 2016).

6. Implications of the AN-1792 active vaccination clinical trial

Neuropathological and biochemical examination of the brains of individuals actively vaccinated with aggregated synthetic A β 1-42 + adjuvant (AN-1792) revealed neuritic and cored plaques were apparently disrupted while diffuse plaques and cerebrovascular amyloid were unaffected (Ferrer et al., 2004; Masliah et al., 2005; Nicoll et al., 2003, 2006; Patton et al., 2006). The cerebral cortex of vaccinated individuals showed a distinctive patchy distribution of neuritic and cored plaques with intercalation of adjacent plaque-poor and plaque-rich areas. In some individuals, the amyloid

plaques left remnants suggestive of 'collapsed plaques' or 'moth-eaten plaques' that were reminiscent of the putative original plaque outline (Ferrer et al., 2004; Masliah et al., 2005; Nicoll et al., 2003, 2006; Patton et al., 2006). In some other instances, remnant structures exhibited a minuscule central deposit of amyloid surrounded by a clear area devoid of amyloid and a thin peripheral 'halo' of amyloid positive material (Patton et al., 2006). ELISA analyses revealed the levels of water-soluble A β 40 and A β 42 were dramatically increased compared to a non-vaccinated AD population. In addition, vaccinated subjects had increased amounts of formic acid/guanidine hydrochloride-extractable A β 40 coupled with a decrease in A β 42 levels (Maarouf et al., 2010).

The above data suggest that, in some vaccinated individuals with high serum antibody titers, the anti-A β antibodies effectively crossed the blood-brain barrier (BBB) and reached their targets. These antibodies were capable of removing amyloid from plaque neuritic haloes and cores, probably from those mainly containing A β 42. The interrupted pattern of plaque loss, however, indicates either variability in vascular antibody permeability or of their action on subtypes of amyloid deposits. Additionally, the patchy plaque elimination could be a consequence of treatment cessation since the trial was discontinued after some patients developed aseptic meningoencephalitis. Interestingly, Holmes et al. (2008) reported that some cases exhibited an almost complete absence of histologically visible amyloid deposits. However, it is likely that some subjects never harbored amyloid deposits in the first place. For instance, case #14, described in reference (Maarouf et al., 2010), reported as having a complete absence of plaques had the lowest levels of A β formic acid extracted A β 40 and A β 42 and no soluble amyloid by immunoassays. However, this subject was Braak stage VI and likely an instance of a primary tauopathy such as progressive supranuclear palsy or corticobasal degeneration.

AN-1792 active vaccination was apparently far more effective at plaque disruption than passive immunizations with monoclonal antibodies. In the former case, multiple polyclonal antibodies recognized a large number of epitopes generated by different A β aggregated conformations. However, in most cases, the clearance of A β deposits was incomplete since diffuse plaques rich in A β 17-42 (P3) and vascular-associated amyloid in cerebral cortex and leptomeningeal vessels, composed primarily of A β 40, were unaffected. Despite the apparent effectiveness of AN-1792 in disrupting at least some amyloid plaques, this therapy notably failed to halt cognitive impairment progression (Holmes et al., 2008).

7. Peripheral A β

Amyloid precursor protein is expressed in most human cells suggesting peptides derived from this molecule, including A β , exist in most tissues and compartments of the body. In addition to the uncertainty over the temporal pace of A β deposition and the sequential location of brain affected sites, the role of A β in circulating plasma and CSF in the development of AD remains enigmatic. Circulating A β is predominately bound to albumin and other plasma molecules (Biere et al., 1996; Bohrmann et al., 1999; Kuo et al., 2000a). Amyloid- β has been detected in peripheral tissues (Roher et al., 2009). For example, in skeletal muscle the levels of A β 42 and total A β are significantly elevated in AD when compared to non-demented controls. Like the brain, skeletal muscle, which represents about one-third of the body mass, also generates a diverse array of A β peptides (Kuo et al., 2000b). Furthermore, the aortas of elderly individuals with severe atherosclerotic deposits contain twice the amount of total A β 40 and A β 42 than subjects with minimal atherosclerotic vascular disease (Kokjohn et al., 2011). Another important source of peripheral A β are the platelets. Quiescent platelets contain more A β 40 than activated de-

granulated ones (Roher et al., 2009). The administration of anti-A β antibody infusions are likely to have some effect on the levels of circulating A β generated in peripheral tissues. Hence, any therapeutic interventions against AD amyloidosis relying only on the levels of circulating A β levels to measure their efficacy may lead to erroneous interpretations. Whether or not circulating A β contributes to the brain pool of these molecules remains to be answered with certainty. The physiologic and health implications of perturbing peripheral A β pools on a chronic basis are unknown.

8. Future biomarker discovery and immunotherapy tactics

While many studies have confirmed the role of A β in AD pathology, there is considerable confusion as to which of its myriad forms will provide effective diagnostic markers and therapeutic targets. Numerous lines of evidence have implicated various A β species including soluble, oligomeric, globular or annular aggregates (Harper et al., 1997; Koffie et al., 2009; Lambert et al., 1998; Lue et al., 1999; McLean et al., 1999; Walsh et al., 1999, 2002; Wang et al., 2002) as critical players in synaptic demise and early memory loss of AD. Likewise, there is no consensus regarding the form(s) of covalently modified A β most intimately involved in neurological decline. There is also considerable uncertainty over where A β accumulation first occurs in the brain and whether the deposited molecules are generated within the brain exclusively or augmented by peripheral pools. Under normal circumstances A β is proteolytically degraded in brain or cleared by the liver and kidneys (Ghisso et al., 2004; Miners et al., 2008; Saito and Ihara, 2014), but very little is known about the catabolism of the PTM A β peptides. Adding to these complexities, a variety of homogeneous or heterogeneous aggregated A β species could be stochastically generated in brain tissue. In some regions of the AD brain up to 12 copies of the APP gene have been found in some neurons. Expression of all or some of these APP genes may participate the pathogenesis of AD (Bushman et al., 2015; Lodato et al., 2015). Different A β peptide species may play distinct roles that are dictated by their specific molecular conformations.

Identification of A β related antibodies that selectively recognize conformational epitopes in different AD patients is an ideal approach for the development of biomarkers and therapeutic agents. Antibodies against A β oligomers have been utilized to confirm the existence and role of oligomeric A β species (Kayed et al., 2003; Koffie et al., 2009; Lambert et al., 1998; Klein et al., 2004; Lacor et al., 2004; Lee et al., 2006b). The most useful A β antibodies for biomarker discovery might be those targeting specific epitopes on molecules known to be widely distributed in AD subjects.

Novel methods have achieved this goal by combining the imaging capabilities of atomic force microscopy with phage display antibody technology which enables the identification of specific protein variants and isolation of reagents that selectively bind the target protein (Barkhordarian et al., 2006). These technologies permit the generation of antibody based (nanobody) reagents that preferentially differentiate toxic-disease associated variants of key neuronal proteins including A β , tau, TDP43 and α -synuclein (Barkhordarian et al., 2006; Emadi et al., 2004, 2007, 2009; Kasturirangan et al., 2012; Kasturirangan et al., 2013; Liu et al., 2004; Zameer et al., 2006, 2008; Zhou et al., 2004). In the case of A β , nanobodies revealed three conformationally distinct oligomeric variants that differentiate postmortem AD brain specimens from healthy or Parkinson's disease cases (Zameer et al., 2008; Kasturirangan et al., 2010; Sierks et al., 2011; Williams et al., 2016). These observations indicate that detection of disease related protein variants may be a powerful blood or CSF based biomarker tool for AD and related neurodegenerative diseases.

Since A β is such a complex protein and AD is a heterogeneous disease, detection of specific A β variants and other related deviant proteins have great promise as individualized biomarkers for AD and great potential for precision-personalized medicine.

9. Conclusions

At the center of the AD-amyloid conundrum is the unresolved observation that in the absence of genetic mutations A β peptides spontaneously aggregate into amyloid plaques and the walls of the cerebral vasculature. We contend this apparently spontaneous change is enhanced by alterations gene expression and PTM of the A β peptide structures which increases their stability and promotes their preferential propagation throughout the brain.

It is unclear whether the widely accepted assumption that unmodified, full length A β 40/A β 42/A β 43 and their soluble/oligomeric/fibrillary forms are the main culprits responsible for the pathology and clinical manifestations of late-onset AD. Experimental investigations reveal the A β molecules harbored by AD subjects are structurally diverse with different conformations and biological properties. However, to date most passive A β immunotherapies, with the exception of aducanumab, have targeted relatively short linear A β 1–42 amino acid sequences rather than specifically folded tertiary structures.

Mounting evidence suggests that pathologic prions derived from normal proteins underlie several neurologic diseases including AD. Prion strains exhibit unique biochemical properties imparted by specific toxic molecular conformations and these strain-specific pathologic structures are faithfully replicated (Watts et al., 2014). Conformational alterations induced by PTM of A β to yield unique amyloid strains may partially account for the clinical and pathological heterogeneity of LOAD (Watts et al., 2014). Analogous to situations in which transmissible prions cross species barriers, the modified A β molecules of AD subjects would induce to adopt and propagate the specific toxic conformation of spontaneously emerging pathologic seeds. Self-transmissible A β strains capable of inducing distinct pathologic manifestations have been isolated from AD subjects (Watts et al., 2014).

To date, A β physical diversity and functional significance of 3D conformations to dementia emergence and neurotoxicity have been almost ignored. In addition to these differing biophysical features among A β species, quantitative differences in the proclivity to accumulate may also contribute to their pathological oligomerization and deposition in the aging brain. It can be assumed that some of these A β -related molecules have positive adaptive functions while others may be detrimental to brain homeostasis. Several lines of circumstantial and experimental evidence have suggested that under damaging conditions such as brain trauma, microbial invasion, a leaky blood-brain barrier and hypertensive crisis, sustained overproduction of some A β peptides may have a rescue function. This assumption is supported by the molecular conservation of the A β amino acid sequence along mammalian evolution that suggests important adaptive values for these peptides. It is still unclear which A β alternatives, including PTM peptides, are involved in the onset and progression of AD and thus might represent the best therapeutic targets, or, alternatively, which may have a salvage function.

We propose that amplified production of some A β species, probably complicated by reduced proteolytic degradation occurring during aging, creates a diverse spectrum of molecules which ultimately disrupt brain homeostasis and contribute to AD neurodegeneration. We postulate that the generation of some specific 3D-peptide conformations of A β impart a unique array of biophysical properties with deleterious as well as protective effects. Proteolytic processing of the highly evolutionarily-conserved

multifunctional APP molecule is capable of creating over a dozen of proteolytically-derived peptides which are involved in a large number of brain functions, some of them with deleterious properties. The APP dynamics must be finely tuned through transcription and translation and closely regulated in terms of proteolytic processing and degradation. In addition to A β , the excessive production of multiple neurotoxic peptides derived from the proteolysis of APP may play important roles in the development of late-onset AD. Some of these APP peptides may be involved in the initial stages of AD and could have profound effects in subsequent neurodegeneration.

One factor confounding the interpretation of previous clinical trials is the observation that a large fraction of elderly dementia cases, even those with clinical manifestations of AD do not harbor conventionally defined AD neuropathology based on densities and distributions of plaques and tangles (Beach et al., 2012). The A/T/N classification scheme of Jack et al. (2016b), proposes to integrate additional markers of neurodegeneration into a nosological partition of AD and other dementias, helping to define clinical subgroups. Coupled with imaging methods capable of revealing amyloid and tangle deposits in living subjects and correlated with clinical signs and symptoms, this more nuanced view of dementia may aid in the design and interpretation of future clinical trials.

Advances in imaging techniques, genetics and neurochemistry will further enable investigators to classify demented subjects on the basis of amyloid or tau deposition patterns with unprecedented precision. Sophisticated, minimally-invasive biopsy methods (Serrano et al., 2015), coupled with innovative analytical techniques would help clarify the effects of A β molecular diversity on pathogenesis and aid in the identification of additional pathologies including tau, α -synuclein and TDP-43. Longitudinal studies combining imaging, molecular fingerprinting and cognitive function exams may reveal if the kinetics assumed for the amyloid cascade hypothesis holds for the majority or only a limited number of AD demented subjects. Clarifying which of the structurally altered A β peptides are responsible for neurotoxicity will help in the design of specific therapeutic interventions. Reagents that selectively recognize and target different A β conformational variants will be powerful tools to assist in the individual diagnosis and personalized treatment of AD patients. Detailed examinations of the non-demented oldest-old subjects retaining cognitive function while harboring the neuropathologic lesions of AD may help reveal which amyloid species are inimical to neuronal and vascular function and which may be comparatively less toxic or non-toxic.

Competing interests

Roher AE, Clarke SG, Kokjohn TA, Maarouf CL, Sierks MR and Serrano G, have no conflicts of interest to declare.

Sabbagh MS is a consultant for: Axovant, Biogen, Grifols, Humana, Lilly pharmaceuticals, Sanofi and vTv Therapeutics. He receives research grant support from: Astra Seneca, Avid Pharmaceuticals, Axovant, Genentech Inc., Lilly Pharmaceuticals, Merck and Co., Pfizer, Roche Diagnostics Corp., vTv Therapeutics and Piramal Imaging. He is a stock shareholder of Brain Health, Muses Labs., and Versanum.

Beach TG is an advisory board member for Genentech, consultant for Avid Radiopharmaceuticals and GE Healthcare, has research contracts with Avid Radiopharmaceuticals and Navidea Biopharmaceuticals, and receives grant support from the National Institutes of Health, the Michael J. Fox Foundation for Parkinson's Research and the State of Arizona.

Acknowledgements

This study was supported by: The National Institute on Aging grants R01 AG019795 (AER), Midwestern University, Glendale, AZ (TAK), The Life Extension Foundation, Inc. and the Elizabeth and Thomas Plott Chair in Gerontology of the UCLA Longevity Center (SGC), and the Arizona Alzheimer's Disease Consortium and from the Department of Defense (W81XWH-14-1-0467) (MRS). Detailed Abeta studies were made possible by the Brain and Body Donation Program at Banner Sun Health Research Institute, which has been supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's Research. The funders had no role in study design, data collection, analysis or interpretation of data, decision to publish or preparation of the manuscript.

References

- Abraham, C.R., 2001. Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease. *Neurobiol. Aging* 22, 931–936.
- Abraham, C.R., Selkoe, D.J., Potter, H., 1988. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. *Cell* 52, 487–501.
- Ali, F.E., Separovic, F., Barrow, C.J., Cherny, R.A., Fraser, F., Bush, A.I., Masters, C.L., Barnham, K.J., 2005. Methionine regulates copper/hydrogen peroxide oxidation products of Abeta. *J. Pept. Sci.* 11, 353–360.
- Alies, B., Eury, H., Bijani, C., Rechinat, L., Faller, P., Hureau, C., 2011. pH-Dependent Cu(II) coordination to amyloid-beta peptide: impact of sequence alterations, including the H6R and D7N familial mutations. *Inorg. Chem.* 50, 11192–11201.
- Andrew, R.J., Kellett, K.A., Thinakaran, G., Hooper, N.M., 2016. A Greek tragedy: the growing complexity of alzheimer amyloid precursor protein proteolysis. *J. Biol. Chem.* 291, 19235–19244.
- Balducci, C., Forloni, G., 2014. In vivo application of beta amyloid oligomers: a simple tool to evaluate mechanisms of action and new therapeutic approaches. *Curr. Pharm. Des.* 20, 2491–2505.
- Barkhordarian, H., Emadi, S., Schulz, P., Sierks, M.R., 2006. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. *Protein Eng. Des. Sel.* 19, 497–502.
- Beach, T.G., Monsell, S.E., Phillips, L.E., Kukull, W., 2012. Accuracy of the clinical diagnosis of alzheimer disease at national institute on aging alzheimer disease centers, 2005–2010. *J. Neuropathol. Exp. Neurol.* 71, 266–273.
- Berger-Sweeney, J., McPhie, D.L., Arters, J.A., Greenan, J., Oster-Granite, M.L., Neve, R.L., 1999. Impairments in learning and memory accompanied by neurodegeneration in mice transgenic for the carboxyl-terminus of the amyloid precursor protein. *Brain Res. Mol. Brain Res.* 66, 150–162.
- Bertrand, E., Brouillet, E., Caille, I., Bouillot, C., Cole, G.M., Prochiantz, A., Allinquant, B., 2001. A short cytoplasmic domain of the amyloid precursor protein induces apoptosis in vitro and in vivo. *Mol. Cell Neurosci.* 18, 503–511.
- Bezprozvanny, I., Mattson, M.P., 2008. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. *Trends Neurosci.* 31, 454–463.
- Biere, A.L., Ostaszewski, B., Stimson, E.R., Hyman, B.T., Maggio, J.E., Selkoe, D.J., 1996. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. *J. Biol. Chem.* 271, 32916–32922.
- Bohme, L., Hoffmann, T., Manhart, S., Wolf, R., Demuth, H.U., 2008. Isoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential beta-secretases. *Biol. Chem.* 389, 1055–1066.
- Bohrmann, B., Tjernberg, L., Kuner, P., Poli, S., Levett-Trafit, B., Naslund, J., Richards, G., Huber, W., Dobeli, H., Nordstedt, C., 1999. Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. *J. Biol. Chem.* 274, 15990–15995.
- Boyle, P.A., Wilson, R.S., Yu, L., Barr, A.M., Honer, W.G., Schneider, J.A., Bennett, D.A., 2013. Much of late life cognitive decline is not due to common neurodegenerative pathologies. *Ann. Neurol.* 74, 478–489.
- Brouillette, J., 2014. The effects of soluble Abeta oligomers on neurodegeneration in Alzheimer's disease. *Curr. Pharm. Des.* 20, 2506–2519.
- Brown, A.M., Lemkul, J.A., Schaum, N., Bevan, D.R., 2014. Simulations of monomeric amyloid beta-peptide (1–40) with varying solution conditions and oxidation state of Met35: implications for aggregation. *Arch. Biochem. Biophys.* 545, 44–52.
- Bushman, D.M., Kaeser, G.E., Siddoway, B., Westra, J.W., Rivera, R.R., Rehen, S.K.,

- Yung, Y.C., Chun, J., 2015. Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer's disease brains. *Elife* 4, e05116.
- Butterfield, D.A., Kanski, J., 2002. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide 1–42. *Peptides* 23, 1299–1309.
- Butterfield, D.A., Galvan, V., Lange, M.B., Tang, H., Sowell, R.A., Spilman, P., Fombonne, J., Gorostiza, O., Zhang, J., Sultana, R., Bredesen, D.E., 2010. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid beta-peptide of APP. *Free Radic. Biol. Med.* 48, 136–144.
- Carnevale, D., Mascio, G., D'Andrea, I., Fardella, V., Bell, R.D., Branchi, I., Pallante, F., Zlokovic, B., Yan, S.S., Lembo, G., 2012. Hypertension induces brain beta-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. *Hypertension* 60, 188–197.
- Chaney, M.O., Webster, S.D., Kuo, Y.M., Roher, A.E., 1998. Molecular modeling of the Abeta1–42 peptide from Alzheimer's disease. *Protein Eng.* 11, 761–767.
- Chetelat, G., 2013. Alzheimer disease: abeta-independent processes-rethinking preclinical AD. *Nat. Rev. Neurol.* 9, 123–124.
- Crouch, P.J., Blake, R., Duce, J.A., Ciccosto, G.D., Li, Q.X., Barnham, K.J., Curtain, C.C., Cherny, R.A., Cappai, R., Dyrks, T., Masters, C.L., Trounce, I.A., 2005. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1–42. *J. Neurosci.* 25, 672–679.
- Dai, S., Ni, W., Patananan, A.N., Clarke, S.G., Karger, B.L., Zhou, Z.S., 2013. Integrated proteomic analysis of major isoaspartyl containing protein in the urine of wild and protein L-isoaspartate O-methyltransferase deficient mice. *Anal. Chem.* 85, 2423–2430.
- D'Arrigo, C., Tabaton, M., Perico, A., 2009. N-terminal truncated pyroglutamy beta amyloid peptide AbetaP3–42 shows a faster aggregation kinetics than the full-length Abeta1–42. *Biopolymers* 91, 861–873.
- De Kimpe, L., van Haastert, E.S., Kaminari, A., Zwart, R., Rutjes, H., Hoozemans, J.J., Scheper, W., 2013. Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Abeta pathology at the lysosome. *Age (Dordr)* 35, 673–687.
- Deane, R., Du, Y.S., Subramanyam, R.K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., Zhu, H., Ghiso, J., Frangione, B., Stern, A., Schmidt, A.M., Armstrong, D.L., Arnold, B., Liliensiek, B., Nawroth, P., Hofman, F., Kindy, M., Stern, D., Zlokovic, B., 2003. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. *Nat. Med.* 9, 907–913.
- DeMattos, R.B., Lu, J., Tang, Y., Racke, M.M., DeLong, C.A., Tzaferis, J.A., Hole, J.T., Forster, B.M., McDonnell, P.C., Liu, F., Kinley, R.D., Jordan, W.H., Hutton, M.L., 2012. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. *Neuron* 76, 908–920.
- Deshpande, A., Mina, E., Glabe, C., Busciglio, J., 2006. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. *J. Neurosci.* 26, 6011–6018.
- Eisele, Y.S., Fritschi, S.K., Hamaguchi, T., Obermuller, U., Fuger, P., Skodras, A., Schafer, C., Odenthal, J., Heikenwalder, M., Staufenbiel, M., Jucker, M., 2014. Multiple factors contribute to the peripheral induction of cerebral beta-amyloidosis. *J. Neurosci.* 34, 10264–10273.
- Emadi, S., Liu, R., Yuan, B., Schulz, P., McAllister, C., Lyubchenko, Y., Messer, A., Sierks, M.R., 2004. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. *Biochemistry* 43, 2871–2878.
- Emadi, S., Barkhordarian, H., Wang, M.S., Schulz, P., Sierks, M.R., 2007. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. *J. Mol. Biol.* 368, 1132–1144.
- Emadi, S., Kasturirangan, S., Wang, M.S., Schulz, P., Sierks, M.R., 2009. Detecting morphologically distinct oligomeric forms of alpha-synuclein. *J. Biol. Chem.* 284, 11048–11058.
- Fabian, H., Szendrei, G.L., Mantsch, H.H., Greenberg, B.D., Otvos Jr., L., 1994. Synthetic post-translationally modified human A beta peptide exhibits a markedly increased tendency to form beta-pleated sheets in vitro. *Eur. J. Biochem.* 221, 959–964.
- Fandrich, M., 2012. Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity. *J. Mol. Biol.* 421, 427–440.
- Ferrer, I., Boada, R.M., Sanchez Guerra, M.L., Rey, M.J., Costa-Jussa, F., 2004. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. *Brain Pathol.* 14, 11–20.
- Fossati, S., Todd, K., Sotolongo, K., Ghiso, J., Rostagno, A., 2013. Differential contribution of isoaspartate post-translational modifications to the fibrillization and toxic properties of amyloid beta and the Asn23 Iowa mutation. *Biochem. J.* 456, 347–360.
- Frost, J.L., Liu, B., Kleinschmidt, M., Schilling, S., Demuth, H.U., Lemere, C.A., 2012. Passive immunization against pyroglutamate-3 amyloid-beta reduces plaque burden in Alzheimer-like transgenic mice: a pilot study. *Neurodegener. Dis.* 10, 265–270.
- Fukuda, H., Shimizu, T., Nakajima, M., Mori, H., Shirasawa, T., 1999. Synthesis, aggregation, and neurotoxicity of the Alzheimer's Abeta1–42 amyloid peptide and its isoaspartyl isomers. *Bioorg. Med. Chem. Lett.* 9, 953–956.
- Fung, J., Frost, D., Chakrabarty, A., McLaurin, J., 2004. Interaction of human and mouse Abeta peptides. *J. Neurochem.* 91, 1398–1403.
- Garzon-Rodriguez, W., Sepulveda-Becerra, M., Milton, S., Glabe, C.G., 1997. Soluble amyloid Abeta-(1–40) exists as a stable dimer at low concentrations. *J. Biol. Chem.* 272, 21037–21044.
- Geiger, T., Clarke, S., 1987. Deamidation, isomerization, and racemization at asparaginy and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. *J. Biol. Chem.* 262, 785–794.
- Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., Frangione, B., 2004. Systemic catabolism of Alzheimer's Abeta40 and Abeta42. *J. Biol. Chem.* 279, 45897–45908.
- Goedert, M., Spillantini, M.G., Cairns, N.J., Crowther, R.A., 1992. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. *Neuron* 8, 159–168.
- Gowing, E., Roher, A.E., Woods, A.S., Cotter, R.J., Chaney, M., Little, S.P., Ball, M.J., 1994. Chemical characterization of A beta 17–42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. *J. Biol. Chem.* 269, 10987–10990.
- Gunn, A.P., Masters, C.L., Cherny, R.A., 2010. Pyroglutamate-Abeta: role in the natural history of Alzheimer's disease. *Int. J. Biochem. Cell Biol.* 42, 1915–1918.
- Hadley, K.C., Rakhit, R., Guo, H., Sun, Y., Jonkman, J.E., McLaurin, J., Hazrati, L.N., Emili, A., Chakrabarty, A., 2015. Determining composition of micron-scale protein deposits in neurodegenerative disease by spatially targeted optical microproteomics. *Elife* 4.
- Harigaya, Y., Shoji, M., Kawarabayashi, T., Kanai, M., Nakamura, T., Iizuka, T., Igeta, Y., Saido, T.C., Sahara, N., Mori, H., Hirai, S., 1995. Modified amyloid beta protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease. *Biochem. Biophys. Res. Commun.* 211, 1015–1022.
- Harigaya, Y., Saido, T.C., Eckman, C.B., Prada, C.M., Shoji, M., Younkin, S.G., 2000. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. *Biochem. Biophys. Res. Commun.* 276, 422–427.
- Harper, J.D., Wong, S.S., Lieber, C.M., Lansbury, P.T., 1997. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. *Chem. Biol.* 4, 119–125.
- Hartmann, T., Bieger, S.C., Bruhl, B., Tienari, P.J., Ida, N., Allsop, D., Roberts, G.W., Masters, C.L., Dotti, C.G., Unsicker, K., Beyreuther, K., 1997. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. *Nat. Med.* 3, 1016–1020.
- He, W., Barrow, C.J., 1999. The A beta 3-pyroglutamy and 11-pyroglutamy peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. *Biochemistry* 38, 10871–10877.
- Herrup, K., 2015. The case for rejecting the amyloid cascade hypothesis. *Nat. Neurosci.* 18, 794–799.
- Higgins, L.S., Murphy Jr., G.M., Forno, L.S., Catalano, R., Cordell, B., 1996. P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. *Am. J. Pathol.* 149, 585–596.
- Hilbich, C., Kisters-Woike, B., Reed, J., Masters, C.L., Beyreuther, K., 1991. Human and rodent sequence analogs of Alzheimer's amyloid beta A4 share similar properties and can be solubilized in buffers of pH 7.4. *Eur. J. Biochem.* 201, 61–69.
- Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R.W., Bullock, R., Love, S., Neal, J.W., Zotova, E., Nicoll, J.A., 2008. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. *Lancet* 372, 216–223.
- Hong, S., Ostaszewski, B.L., Yang, T., O'Malley, T.T., Jin, M., Yanagisawa, K., Li, S., Bartels, T., Selkoe, D.J., 2014. Soluble abeta oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. *Neuron* 82, 308–319.
- Hori, Y., Hashimoto, T., Wakutani, Y., Urakami, K., Nakashima, K., Condrion, M.M., Tsubuki, S., Saido, T.C., Teplow, D.B., Iwatsubo, T., 2007. The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate Abeta fibril formation without increasing protofibril formation. *J. Biol. Chem.* 282, 4916–4923.
- Hosoda, R., Saido, T.C., Otvos Jr., L., Arai, T., Mann, D.M., Lee, V.M., Trojanowski, J.Q., Iwatsubo, T., 1998. Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains. *J. Neuropathol. Exp. Neurol.* 57, 1089–1095.
- Hou, L., Kang, L., Marchant, R.E., Zagorski, M.G., 2002. Methionine 35 oxidation reduces fibril assembly of the amyloid abeta-(1–42) peptide of Alzheimer's disease. *J. Biol. Chem.* 277, 40173–40176.
- Hou, L., Lee, H.G., Han, F., Tedesco, J.M., Perry, G., Smith, M.A., Zagorski, M.G., 2013. Modification of amyloid-beta1–42 fibril structure by methionine-35 oxidation. *J. Alzheimers Dis.* 37, 9–18.
- Hughes, T.M., Lopez, O.L., Evans, R.W., Kamboh, M.I., Williamson, J.D., Klunk, W.E., Mathis, C.A., Price, J.C., Cohen, A.D., Snitz, B.E., Dekosky, S.T., Kuller, L.H., 2014. Markers of cholesterol transport are associated with amyloid deposition in the brain. *Neurobiol. Aging* 35, 802–807.
- Hung, L.W., Ciccosto, G.D., Giannakis, E., Tew, D.J., Perez, K., Masters, C.L., Cappai, R., Wade, J.D., Barnham, K.J., 2008. Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: abeta dimers and trimers correlate with neurotoxicity. *J. Neurosci.* 28, 11950–11958.
- Inoue, K., Hosaka, D., Mochizuki, N., Akatsu, H., Tsutsumiuchi, K., Hashizume, Y., Matsukawa, N., Yamamoto, T., Toyooka, T., 2014. Simultaneous determination of post-translational racemization and isomerization of N-terminal amyloid-beta in Alzheimer's brain tissues by covalent chiral derivatized ultraperformance liquid chromatography tandem mass spectrometry. *Anal. Chem.* 86, 797–804.
- Iwatsubo, T., Saido, T.C., Mann, D.M., Lee, V.M., Trojanowski, J.Q., 1996. Full-length amyloid-beta (1–42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. *Am. J. Pathol.* 149, 1823–1830.
- Jack Jr., C.R., Knopman, D.S., Chetelat, G., Dickson, D., Fagan, A.M., Frisoni, G.B., Jagust, W., Mormino, E.C., Petersen, R.C., Sperling, R.A., van Der Flier, W.M.,

- Villemagne, V.L., Visser, P.J., Vos, S.J., 2016. Suspected non-Alzheimer disease pathophysiology - concept and controversy. *Nat. Rev. Neurol.* 12, 117–124.
- Jack Jr., C.R., Bennett, D.A., Blennow, K., Carrillo, M.C., Feldman, H.H., Frisoni, G.B., Hampel, H., Jagust, W.J., Johnson, K.A., Knopman, D.S., Petersen, R.C., Scheltens, P., Sperling, R.A., Dubois, B., 2016. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. *Neurology* 87, 539–547.
- Jang, H., Arce, F.T., Ramachandran, S., Capone, R., Azimova, R., Kagan, B.L., Nussinov, R., Lal, R., 2010. Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's Disease and Down syndrome. *Proc. Natl. Acad. Sci. U. S. A.* 107, 6538–6543.
- Jang, H., Connelly, L., Arce, F.T., Ramachandran, S., Kagan, B.L., Lal, R., Nussinov, R., 2013. Mechanisms for the insertion of toxic, fibril-like beta-amyloid oligomers into the membrane. *J. Chem. Theory Comput.* 9, 822–833.
- Jawhar, S., Wirths, O., Bayer, T.A., 2011. Pyroglutamate amyloid-beta (A β): a hatchet man in Alzheimer disease. *J. Biol. Chem.* 286, 38825–38832.
- Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T.A., Wirths, O., 2012. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal A β aggregation in the 5XFAD mouse model of Alzheimer's disease. *Neurobiol. Aging* 33, 196.e29–196.e40.
- Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., Selkoe, D.J., 2011. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 108, 5819–5824.
- Johansson, A.S., Bergquist, J., Volbracht, C., Paivio, A., Leist, M., Lannfelt, L., Westlind-Danielsson, A., 2007. Attenuated amyloid-beta aggregation and neurotoxicity owing to methionine oxidation. *Neuroreport* 18, 559–563.
- Josephs, K.A., Whitwell, J.L., Ahmed, Z., Shiung, M.M., Weigand, S.D., Knopman, D.S., Boeve, B.F., Parisi, J.E., Petersen, R.C., Dickson, D.W., Jack Jr., C.R., 2008. Beta-amyloid burden is not associated with rates of brain atrophy. *Ann. Neurol.* 63, 204–212.
- Jucker, M., Walker, L.C., 2013. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. *Nature* 501, 45–51.
- Jung, G., Ryu, J., Heo, J., Lee, S.J., Cho, J.Y., Hong, S., 2011. Protein L-isoaspartyl O-methyltransferase inhibits amyloid beta fibrillogenesis in vitro. *Pharmazie* 66, 529–534.
- Kaneko, I., Morimoto, K., Kubo, T., 2001. Drastic neuronal loss in vivo by beta-amyloid racemized at Ser(26) residue: conversion of non-toxic [D-Ser(26)] beta-amyloid 1–40 to toxic and proteinase-resistant fragments. *Neuroscience* 104, 1003–1011.
- Kasturirangan, S., Boddapati, S., Sierks, M.R., 2010. Engineered proteolytic nanobodies reduce A β burden and ameliorate A β -induced cytotoxicity. *Biochemistry* 49, 4501–4508.
- Kasturirangan, S., Li, L., Emadi, S., Boddapati, S., Schulz, P., Sierks, M.R., 2012. Nanobody specific for oligomeric beta-amyloid stabilizes nontoxic form. *Neurobiol. Aging* 33, 1320–1328.
- Kasturirangan, S., Reasoner, T., Schulz, P., Boddapati, S., Emadi, S., Valla, J., Sierks, M.R., 2013. Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples. *Bio-technol. Prog.* 29, 463–471.
- Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., Glabe, C.G., 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science* 300, 486–489.
- Kim, B.H., Palermo, N.Y., Lovas, S., Zaikova, T., Keana, J.F., Lyubchenko, Y.L., 2011. Single-molecule atomic force microscopy force spectroscopy study of A β -40 interactions. *Biochemistry* 50, 5154–5162.
- Kimura, A., Hata, S., Suzuki, T., 2016. Alternative selection of beta-site APP-cleaving enzyme 1 (BACE1) cleavage sites in amyloid beta-protein precursor (APP) harboring protective and pathogenic mutations within the abeta sequence. *J. Biol. Chem.* 291, 24041–24053.
- Kiskis, J., Fink, H., Nyberg, L., Thyr, J., Li, J.Y., Enejder, A., 2015. Plaque-associated lipids in Alzheimer's diseased brain tissue visualized by nonlinear microscopy. *Sci. Rep.* 5, 13489.
- Klein, W.L., 2013. Synaptotoxic amyloid-beta oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? *J. Alzheimer's Dis.* 33 (Suppl 1), S49–S65.
- Klein, W.L., Stine Jr., W.B., Teplow, D.B., 2004. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. *Neurobiol. Aging* 25, 569–580.
- Koffie, R.M., Meyer-Luehmann, M., Hashimoto, T., Adams, K.W., Mielke, M.L., Garcia-Alloza, M., Mischeva, K.D., Smith, S.J., Kim, M.L., Lee, V.M., Hyman, B.T., Spire-Jones, T.L., 2009. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. *Proc. Natl. Acad. Sci. U. S. A.* 106, 4012–4017.
- Kokjohn, T.A., Van Vickle, G.D., Maarouf, C.L., Kalback, W.M., Hunter, J.M., Daugs, I.D., Luehrs, D.C., Lopez, J., Brune, D., Sue, L.I., Beach, T.G., Castano, E.M., Roher, A.E., 2011. Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. *Biochim. Biophys. Acta* 1812, 1508–1514.
- Kokubo, H., Kaye, R., Glabe, C.G., Yamaguchi, H., 2005. Soluble A β oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. *Brain Res.* 1031, 222–228.
- Kubo, T., Nishimura, S., Kumagai, Y., Kaneko, I., 2002. In vivo conversion of racemized beta-amyloid ([D-Ser 26]A β 1–40) to truncated and toxic fragments ([D-Ser 26]A β 25–35/40) and fragment presence in the brains of Alzheimer's patients. *J. Neurosci. Res.* 70, 474–483.
- Kubo, T., Kumagai, Y., Miller, C.A., Kaneko, I., 2003. Beta-amyloid racemized at the Ser26 residue in the brains of patients with Alzheimer disease: implications in the pathogenesis of Alzheimer disease. *J. Neuropathol. Exp. Neurol.* 62, 248–259.
- Kumar, S., Rezaei-Ghaleh, N., Terwel, D., Thal, D.R., Richard, M., Hoch, M., McDonald, J.M., Wullner, U., Glebov, K., Heneka, M.T., Walsh, D.M., Zweckstetter, M., Walter, J., 2011. Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. *EMBO J.* 30, 2255–2265.
- Kumar, S., Wirths, O., Theil, S., Gerth, J., Bayer, T.A., Walter, J., 2013. Early intraneuronal accumulation and increased aggregation of phosphorylated A β in a mouse model of Alzheimer's disease. *Acta Neuropathol.* 125, 699–709.
- Kummer, M.P., Heneka, M.T., 2014. Truncated and modified amyloid-beta species. *Alzheimers Res. Ther.* 6, 28.
- Kummer, M.P., Hermes, M., Delekarte, A., Hammerschmidt, T., Kumar, S., Terwel, D., Walter, J., Pape, H.C., König, S., Roebber, S., Jessen, F., Klockgether, T., Korte, M., Heneka, M.T., 2011. Nitration of tyrosine 10 critically enhances amyloid beta aggregation and plaque formation. *Neuron* 71, 833–844.
- Kuo, Y.M., Emmerling, M.R., Vigo-Pelfrey, C., Kasunic, T.C., Kirkpatrick, J.B., Murdoch, G.H., Ball, M.J., Roher, A.E., 1996. Water-soluble A β (N-40, N-42) oligomers in normal and Alzheimer disease brains. *J. Biol. Chem.* 271, 4077–4081.
- Kuo, Y.M., Emmerling, M.R., Woods, A.S., Cotter, R.J., Roher, A.E., 1997. Isolation, chemical characterization, and quantitation of A β 3-pyroglutamy peptide from neuritic plaques and vascular amyloid deposits. *Biochem. Biophys. Res. Commun.* 237, 188–191.
- Kuo, Y.M., Webster, S., Emmerling, M.R., De Lima, N., Roher, A.E., 1998. Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A β peptides of Alzheimer's disease. *Biochim. Biophys. Acta* 1406, 291–298.
- Kuo, Y.M., Kokjohn, T.A., Kalback, W., Luehrs, D., Galasko, D.R., Chevallier, N., Koo, E.H., Emmerling, M.R., Roher, A.E., 2000. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. *Biochem. Biophys. Res. Commun.* 268, 750–756.
- Kuo, Y.M., Kokjohn, T.A., Watson, M.D., Woods, A.S., Cotter, R.J., Sue, L.I., Kalback, W.M., Emmerling, M.R., Beach, T.G., Roher, A.E., 2000. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of A β metabolism. *Am. J. Pathol.* 156, 797–805.
- Lacor, P.N., Buniel, M.C., Chang, L., Fernandez, S.J., Gong, Y., Viola, K.L., Lambert, M.P., Velasco, P.T., Bigio, E.H., Finch, C.E., Krafft, G.A., Klein, W.L., 2004. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. *J. Neurosci.* 24, 10191–10200.
- LaFerla, F.M., Green, K.N., Oddo, S., 2007. Intracellular amyloid-beta in Alzheimer's disease. *Nat. Rev. Neurosci.* 8, 499–509.
- Lalowski, M., Golabek, A., Lemere, C.A., Selkoe, D.J., Wisniewski, H.M., Beavis, R.C., Frangione, B., Wisniewski, T., 1996. The "nonamyloidogenic" p3 fragment (amyloid beta1–42) is a major constituent of Down's syndrome cerebellar preamyloid. *J. Biol. Chem.* 271, 33623–33631.
- Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Rozovsky, I., Trommer, B., Viola, K.L., Wals, P., Zhang, C., Finch, C.E., Krafft, G.A., Klein, W.L., 1998. Diffusible, nonfibrillar ligands derived from A β 1–42 are potent central nervous system neurotoxins. *Proc. Natl. Acad. Sci. U. S. A.* 95, 6448–6453.
- Larson, M.E., Lesne, S.E., 2012. Soluble A β oligomer production and toxicity. *J. Neurochem.* 120 (Suppl 1), 125–139.
- Lee, J.M., Petrucelli, L., Fisher, G., Ramdath, S., Castillo, J., Di Fiore, M.M., D'Aniello, A., 2002. Evidence for D-aspartyl-beta-amyloid secretase activity in human brain. *J. Neuropathol. Exp. Neurol.* 61, 125–131.
- Lee, H.G., Zhu, X., Nunomura, A., Perry, G., Smith, M.A., 2006. Amyloid beta: the alternate hypothesis. *Curr. Alzheimer Res.* 3, 75–80.
- Lee, E.B., Leng, L.Z., Zhang, B., Kwong, L., Trojanowski, J.Q., Abel, T., Lee, V.M., 2006. Targeting amyloid-beta peptide (A β) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A β precursor protein (APP) transgenic mice. *J. Biol. Chem.* 281, 4292–4299.
- Liao, L., Cheng, D., Wang, J., Duong, D.M., Losik, T.G., Gearing, M., Rees, H.D., Lah, J.J., Levey, A.I., Peng, J., 2004. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. *J. Biol. Chem.* 279, 37061–37068.
- Liao, F., Zhang, T.J., Jiang, H., Lefton, K.B., Robinson, G.O., Vassar, R., Sullivan, P.M., Holtzman, D.M., 2015. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. *Acta Neuropathol. Commun.* 3, 70.
- Liu, R., Yuan, B., Emadi, S., Zameer, A., Schulz, P., McAllister, C., Lyubchenko, Y., Goud, G., Sierks, M.R., 2004. Single chain variable fragments against beta-amyloid (A β) can inhibit A β aggregation and prevent abeta-induced neurotoxicity. *Biochemistry* 43, 6959–6967.
- Lodato, M.A., Woodworth, M.B., Lee, S., Evrony, G.D., Mehta, B.K., Karger, A., Lee, S., Chittenden, T.W., D'Gama, A.M., Cai, X., Luquette, L.J., Lee, E., Park, P.J., Walsh, C.A., 2015. Somatic mutation in single human neurons tracks developmental and transcriptional history. *Science* 350, 94–98.
- Lowenson, J.D., Clarke, S., 1991. Structural elements affecting the recognition of L-isoaspartyl residues by the L-isoaspartyl/D-aspartyl protein methyltransferase. Implications for the repair hypothesis. *J. Biol. Chem.* 266, 19396–19406.

- Lu, D.C., Rabizadeh, S., Chandra, S., Shayya, R.F., Ellerby, L.M., Ye, X., Salvesen, G.S., Koo, E.H., Bredesen, D.E., 2000. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. *Nat. Med.* 6, 397–404.
- Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J.H., Rydel, R.E., Rogers, J., 1999. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. *Am. J. Pathol.* 155, 853–862.
- Lv, Z., Roychoudhuri, R., Condron, M.M., Teplow, D.B., Lyubchenko, Y.L., 2013. Mechanism of amyloid beta-protein dimerization determined using single-molecule AFM force spectroscopy. *Sci. Rep.* 3, 2880.
- Maarouf, C.L., Dausgs, I.D., Kokjohn, T.A., Kalback, W.M., Patton, R.L., Luehrs, D.C., Masliah, E., Nicoll, J.A., Sabbagh, M.N., Beach, T.G., Castano, E.M., Roher, A.E., 2010. The biochemical aftermath of anti-amyloid immunotherapy. *Mol. Neurodegener.* 5, 39.
- Mackic, J.B., Bading, J., Ghiso, J., Walker, L., Wisniewski, T., Frangione, B., Zlokovic, B.V., 2002. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. *Vasc. Pharmacol.* 38, 303–313.
- Madeira, A., Pomet, J.M., Prochiantz, A., Allinquant, B., 2005. SET protein (TAF1-beta, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic subdomain. *FASEB J.* 19, 1905–1907.
- Mandler, M., Rockenstein, E., Ubhi, K., Hansen, L., Adame, A., Michael, S., Galasko, D., Santic, R., Mattner, F., Masliah, E., 2012. Detection of peri-synaptic amyloid-beta pyroglutamate aggregates in early stages of Alzheimer's disease and in AbetaPP transgenic mice using a novel monoclonal antibody. *J. Alzheimers Dis.* 28, 783–794.
- Masliah, E., Hansen, L., Adame, A., Crews, L., Bard, F., Lee, C., Seubert, P., Games, D., Kirby, L., Schenk, D., 2005. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. *Neurology* 64, 129–131.
- Masters, C.L., Selkoe, D.J., 2012. Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease. *Cold Spring Harb. Perspect. Med.* 2, a006262.
- Mattsson, N., Insel, P.S., Palmqvist, S., Stomrud, E., van, W.D., Minthon, L., Zetterberg, H., Blennow, K., Hansson, O., 2016. Increased amyloidogenic APP processing in APOE varepsilon4-negative individuals with cerebral beta-amyloidosis. *Nat. Commun.* 7, 10918.
- McDonald, J.M., Cairns, N.J., Taylor-Reinwald, L., Holtzman, D., Walsh, D.M., 2012. The levels of water-soluble and triton-soluble Abeta are increased in Alzheimer's disease brain. *Brain Res.* 1450, 138–147.
- McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., Bush, A.L., Masters, C.L., 1999. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. *Ann. Neurol.* 46, 860–866.
- Milton, N.G., 2001. Phosphorylation of amyloid-beta at the serine 26 residue by human cdc2 kinase. *Neuroreport* 12, 3839–3844.
- Milton, N.G., 2005. Phosphorylated amyloid-beta: the toxic intermediate in Alzheimer's disease neurodegeneration. *Subcell. Biochem.* 38, 381–402.
- Miners, J.S., Baig, S., Palmer, J., Palmer, L.E., Kehoe, P.G., Love, S., 2008. Abeta-degrading enzymes in Alzheimer's disease. *Brain Pathol.* 18, 240–252.
- Miravalle, L., Calero, M., Takao, M., Roher, A.E., Ghetti, B., Vidal, R., 2005. Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. *Biochemistry* 44, 10810–10821.
- Mori, H., Takio, K., Ogawara, M., Selkoe, D.J., 1992. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. *J. Biol. Chem.* 267, 17082–17086.
- Mori, T., Paris, D., Town, T., Rojiani, A.M., Sparks, D.L., DelleDonne, A., Crawford, F., Abdullah, L.L., Humphrey, J.A., Dickson, D.W., Mullan, M.J., 2001. Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. *J. Neuropathol. Exp. Neurol.* 60, 778–785.
- Moskovitz, J., Maiti, P., Lopes, D.H., Oien, D.B., Attar, A., Liu, T., Mittal, S., Hayes, J., Bitan, G., 2011. Induction of methionine-sulfoxide reductases protects neurons from amyloid beta-protein insults in vitro and in vivo. *Biochemistry* 50, 10687–10697.
- Mucke, L., Selkoe, D.J., 2012. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. *Cold Spring Harb. Perspect. Med.* 2, a006338.
- Mufson, E.J., Benzing, W.C., Cole, G.M., Wang, H., Emerich, D.F., Sladek Jr., J.R., Morrison, J.H., Kordower, J.H., 1994. Apolipoprotein E-immunoreactivity in aged rhesus monkey cortex: colocalization with amyloid plaques. *Neurobiol. Aging* 15, 621–627.
- Mullane, K., Williams, M., 2013. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? *Biochem. Pharmacol.* 85, 289–305.
- Narayanan, S., Kamps, B., Boelens, W.C., Reif, B., 2006. alphaB-crystallin competes with Alzheimer's disease beta-amyloid peptide for peptide-peptide interactions and induces oxidation of Abeta-Met35. *FEBS Lett.* 580, 5941–5946.
- Naslund, J., Karlstrom, A.R., Tjernberg, L.O., Schierhorn, A., Terenius, L., Nordstedt, C., 1996. High-resolution separation of amyloid beta-peptides: structural variants present in Alzheimer's disease amyloid. *J. Neurochem.* 67, 294–301.
- Nelson, P.T., Abner, E.L., Schmitt, F.A., Kryscio, R.J., Jicha, G.A., Smith, C.D., Davis, D.G., Poduska, J.W., Patel, E., Mendiondo, M.S., Markesbery, W.R., 2010. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. *Brain Pathol.* 20, 66–79.
- Nelson, P.T., Alafuzoff, I., Bigio, E.H., Bouras, C., Braak, H., Cairns, N.J., Castellani, R.J., Crain, B.J., Davies, P., Del, T.K., Duyckaerts, C., Frosch, M.P., Haroutunian, V., Hof, P.R., Hulette, C.M., Hyman, B.T., Iwatsubo, T., Jellinger, K.A., Jicha, G.A., Kovari, E., Kukull, W.A., Leverenz, J.B., Love, S., Mackenzie, I.R., Mann, D.M., Masliah, E., McKee, A.C., Montine, T.J., Morris, J.C., Schneider, J.A., Sonnen, J.A., Thal, D.R., Trojanowski, J.Q., Troncoso, J.C., Wisniewski, T., Wolter, R.L., Beach, T.G., 2012. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. *J. Neuropathol. Exp. Neurol.* 71, 362–381.
- Nicoll, J.A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., Weller, R.O., 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. *Nat. Med.* 9, 448–452.
- Nicoll, J.A., Barton, E., Boche, D., Neal, J.W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., Seubert, P., Schenk, D., Holmes, C., 2006. Abeta species removal after abeta42 immunization. *J. Neuropathol. Exp. Neurol.* 65, 1040–1048.
- Nikolaev, A., McLaughlin, T., O'Leary, D.D., Tessier-Lavigne, M., 2009. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. *Nature* 457, 981–989.
- Nussbaum, J.M., Schilling, S., Cynis, H., Silva, A., Swanson, E., Wangsanut, T., Taylor, K., Wiltgen, B., Hatami, A., Ronicke, R., Reymann, K., Hutter-Paier, G., Alexandru, A., Jagla, W., Graubner, S., Glabe, C.G., Demuth, H.U., Bloom, G.S., 2012. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. *Nature* 485, 651–655.
- Ono, K., Condron, M.M., Teplow, D.B., 2010. Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid beta-protein assembly and toxicity. *J. Biol. Chem.* 285, 23186–23197.
- Orpiszewski, J., Benson, M.D., 1999. Induction of beta-sheet structure in amyloidogenic peptides by neutralization of aspartate: a model for amyloid nucleation. *J. Mol. Biol.* 289, 413–428.
- Oster-Granite, M.L., McPhie, D.L., Greenan, J., Neve, R.L., 1996. Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. *J. Neurosci.* 16, 6732–6741.
- Palop, J.J., Mucke, L., 2010. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. *Nat. Neurosci.* 13, 812–818.
- Park, S.A., Shaked, G.M., Bredesen, D.E., Koo, E.H., 2009. Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein. *Biochem. Biophys. Res. Commun.* 388, 450–455.
- Patton, R.L., Kalback, W.M., Esh, C.L., Kokjohn, T.A., Van Vickle, G.D., Luehrs, D.C., Kuo, Y.M., Lopez, J., Brune, D., Ferrer, I., Masliah, E., Newel, A.J., Beach, T.G., Castano, E.M., Roher, A.E., 2006. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. *Am. J. Pathol.* 169, 1048–1063.
- Perez-Garmendia, R., Gevorkian, G., 2013. Pyroglutamate-modified amyloid beta peptides: emerging targets for Alzheimer's disease immunotherapy. *Curr. Neuropharmacol.* 11, 491–498.
- Pike, C.J., Overman, M.J., Cotman, C.W., 1995. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. *J. Biol. Chem.* 270, 23895–23898.
- Portelius, E., Bogdanovic, N., Gustavsson, M.K., Volkman, I., Brinkmalm, G., Zetterberg, H., Winblad, B., Blennow, K., 2010. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. *Acta Neuropathol.* 120, 185–193.
- Prohovnik, I., Perl, D.P., Davis, K.L., Libow, L., Lesser, G., Haroutunian, V., 2006. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. *Neurology* 66, 49–55.
- Prusiner, S.B., 2012. Cell biology. A unifying role for prions in neurodegenerative diseases. *Science* 336, 1511–1513.
- Prusiner, S.B., 2013. Biology and genetics of prions causing neurodegeneration. *Annu. Rev. Genet.* 47, 601–623.
- Qi-Takahara, Y., Morishima-Kawashima, M., Tanimura, Y., Dolios, G., Hirotsu, N., Horikoshi, Y., Kametani, F., Maeda, M., Saido, T.C., Wang, R., Ihara, Y., 2005. Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. *J. Neurosci.* 25, 436–445.
- Radkiewicz, J.L., Zipse, H., Clarke, S., Houk, K.N., 1996. Accelerated Racemization of Aspartic Acid and Asparagine Residues via Succinimide Intermediates: an Ab Initio Theoretical Exploration of Mechanism, vol. 118, pp. 9148–9155.
- Reddy, P.H., 2009. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. *Exp. Neurol.* 218, 286–292.
- Roher, A.E., Lowenson, J.D., Clarke, S., Wolkow, C., Wang, R., Cotter, R.J., Reardon, I.M., Zurcher-Neely, H.A., Heinrikson, R.L., Ball, M.J., 1993. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. *J. Biol. Chem.* 268, 3072–3083.
- Roher, A.E., Lowenson, J.D., Clarke, S., Woods, A.S., Cotter, R.J., Gowing, E., Ball, M.J., 1993. beta-Amyloid-(1–42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. *Proc. Natl. Acad. Sci. U. S. A.* 90, 10836–10840.
- Roher, A.E., Chaney, M.O., Kuo, Y.M., Webster, S.D., Stine, W.B., Haverkamp, L.J., Woods, A.S., Cotter, R.J., Tuohy, J.M., Krafft, G.A., Bonnell, B.S., Emmerling, M.R., 1996. Morphology and toxicity of Abeta-(1–42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. *J. Biol. Chem.* 271, 20631–20635.
- Roher, A.E., Esh, C.L., Kokjohn, T.A., Castano, E.M., Van Vickle, G.D., Kalback, W.M., Patton, R.L., Luehrs, D.C., Dausgs, I.D., Kuo, Y.M., Emmerling, M.R., Soares, H., Quinn, J.F., Kaye, J., Connor, D.J., Silverberg, N.B., Adler, C.H., Seward, J.D., Beach, T.G., Sabbagh, M.N., 2009. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. *Alzheimers Dement.* 5, 18–29.

- Roychaudhuri, R., Zheng, X., Lomakin, A., Maiti, P., Condrón, M.M., Benedek, G.B., Bitan, G., Bowers, M.T., Teplow, D.B., 2015. Role of species-specific primary structure differences in Abeta42 assembly and neurotoxicity. *ACS Chem. Neurosci.* 6, 1941–1955.
- Russo, C., Saido, T.C., DeBusk, L.M., Tabaton, M., Gambetti, P., Teller, J.K., 1997. Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains. *FEBS Lett.* 409, 411–416.
- Russo, C., Violani, E., Salis, S., Venezia, V., Dolcini, V., Damonte, G., Benatti, U., D'Arrigo, C., Patrone, E., Carlo, P., Schettini, G., 2002. Pyroglutamate-modified amyloid beta-peptides—AbetaN3(pE)—strongly affect cultured neuron and astrocyte survival. *J. Neurochem.* 82, 1480–1489.
- Saido, T.C., Iwatsubo, T., Mann, D.M., Shimada, H., Ihara, Y., Kawashima, S., 1995. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. *Neuron* 14, 457–466.
- Saito, S., Ihara, M., 2014. New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. *Front. Aging Neurosci.* 6, 290.
- Schilling, S., Lauber, T., Schaupp, M., Manhart, S., Scheel, E., Bohm, G., Demuth, H.U., 2006. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). *Biochemistry* 45, 12393–12399.
- Schlenzig, D., Ronnicke, R., Cynis, H., Ludwig, H.H., Scheel, E., Reymann, K., Saido, T., Hause, G., Schilling, S., Demuth, H.U., 2012. N-Terminal pyroglutamate formation of Abeta38 and Abeta40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation. *J. Neurochem.* 121, 774–784.
- Schmidt, M., Rohou, A., Lasker, K., Yadav, J.K., Schiene-Fischer, C., Fandrich, M., Grigorieff, N., 2015. Peptide dimer structure in an Abeta(1–42) fibril visualized with cryo-EM. *Proc. Natl. Acad. Sci. U. S. A.* 112, 11858–11863.
- Selkoe, D.J., 2008. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. *Behav. Brain Res.* 192, 106–113.
- Selkoe, D.J., Hardy, J., 2016. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol. Med.* 8, 595–608.
- Selkoe, D.J., Wolfe, M.S., 2007. Presenilin: running with scissors in the membrane. *Cell* 131, 215–221.
- Sengupta, U., Nilson, A.N., Kaye, R., 2016. The role of amyloid-beta oligomers in toxicity, propagation, and immunotherapy. *EBioMedicine* 6, 42–49.
- Sergeant, N., Bombois, S., Ghestem, A., Drobecq, H., Kostañjevecki, V., Missiaen, C., Watzte, A., David, J.P., Vanmechelen, E., Sergheraert, C., Delacourte, A., 2003. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. *J. Neurochem.* 85, 1581–1591.
- Serrano, G.E., Intorcchia, A., Carew, J., Chiarolanza, G., Hidalgo, J.A., Sue, L.I., Dugger, B.N., Saxon-Labelle, M., Filon, J., Scroggins, A., Pullen, J., Fornwalt, B.E., Scott, S., Sabbagh, M.N., Adler, C.H., Akiyama, H., Beach, T.G., 2015. Feasibility study: comparison of frontal cortex needle core versus open biopsy for detection of characteristic proteinopathies of neurodegenerative diseases. *J. Neuropathol. Exp. Neurol.* 74, 934–942.
- Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., Regan, C.M., Walsh, D.M., Sabatini, B.L., Selkoe, D.J., 2008. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat. Med.* 14, 837–842.
- Shimizu, T., Watanabe, A., Ogawara, M., Mori, H., Shirasawa, T., 2000. Isoaspartate formation and neurodegeneration in Alzheimer's disease. *Arch. Biochem. Biophys.* 381, 225–234.
- Shimizu, T., Matsuoka, Y., Shirasawa, T., 2005. Biological significance of isoaspartate and its repair system. *Biol. Pharm. Bull.* 28, 1590–1596.
- Shin, Y., Cho, H.S., Fukumoto, H., Shimizu, T., Shirasawa, T., Greenberg, S.M., Rebeck, G.W., 2003. Abeta species, including IsoAsp23 Abeta, in low-type familial cerebral amyloid angiopathy. *Acta Neuropathol.* 105, 252–258.
- Shivers, B.D., Hilbich, C., Multhaup, G., Salbaum, M., Beyreuther, K., Seeburg, P.H., 1988. Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact. *EMBO J.* 7, 1365–1370.
- Sierks, M.R., Chatterjee, G., McGraw, C., Kasturirangan, S., Schulz, P., Prasad, S., 2011. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. *Integr. Biol. (Camb.)* 3, 1188–1196.
- Simons, M., De, S.B., Multhaup, G., Tienari, P.J., Dotti, C.G., Beyreuther, K., 1996. Amyloidogenic processing of the human amyloid precursor protein in primary cultures of rat hippocampal neurons. *J. Neurosci.* 16, 899–908.
- Stewart, K.L., Hughes, E., Yates, E.A., Akiel, G.R., Huang, T.Y., Lima, M.A., Rudd, T.R., Guerrini, M., Hung, S.C., Radford, S.E., Middleton, D.A., 2016. Atomic details of the interactions of glycosaminoglycans with amyloid-beta fibrils. *J. Am. Chem. Soc.* 138, 8328–8331.
- Sun, N., Hartmann, R., Lecher, J., Stoldt, M., Funke, S.A., Gremer, L., Ludwig, H.H., Demuth, H.U., Kleinschmidt, M., Willbold, D., 2012. Structural analysis of the pyroglutamate-modified isoform of the Alzheimer's disease-related amyloid-beta using NMR spectroscopy. *J. Pept. Sci.* 18, 691–695.
- Szendrei, G.I., Fabian, H., Mantsch, H.H., Lovas, S., Nyeki, O., Schon, I., Otvos Jr., L., 1994. Aspartate-bond isomerization affects the major conformations of synthetic peptides. *Eur. J. Biochem.* 226, 917–924.
- Szendrei, G.I., Prammer, K.V., Vasko, M., Lee, V.M., Otvos Jr., L., 1996. The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid beta-peptide as modeled with N-terminal decapeptide fragments. *Int. J. Pept. Protein Res.* 47, 289–296.
- Tabaton, M., Nunzi, M.G., Xue, R., Usiak, M., Autilio-Gambetti, L., Gambetti, P., 1994. Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. *Biochem. Biophys. Res. Commun.* 200, 1598–1603.
- Takami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., Ihara, Y., 2009. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. *J. Neurosci.* 29, 13042–13052.
- Tambo, K., Yamaguchi, T., Kobayashi, K., Terauchi, E., Ichi, I., Kojo, S., 2013. Racemization of the aspartic acid residue of amyloid-beta peptide by a radical reaction. *Biosci. Biotechnol. Biochem.* 77, 416–418.
- Tekirian, T.L., Saido, T.C., Markesbery, W.R., Russell, M.J., Wekstein, D.R., Patel, E., Geddes, J.W., 1998. N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. *J. Neuropathol. Exp. Neurol.* 57, 76–94.
- Teller, J.K., Russo, C., DeBusk, L.M., Angelini, G., Zaccaro, D., Dagna-Bricarelli, F., Scartzzini, P., Bertolini, S., Mann, D.M., Tabaton, M., Gambetti, P., 1996. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. *Nat. Med.* 2, 93–95.
- Tomidokoro, Y., Rostagno, A., Neubert, T.A., Lu, Y., Rebeck, G.W., Frangione, B., Greenberg, S.M., Ghiso, J., 2010. Iowa variant of familial Alzheimer's disease: accumulation of posttranslationally modified AbetaD23N in parenchymal and cerebrovascular amyloid deposits. *Am. J. Pathol.* 176, 1841–1854.
- Tu, S., Okamoto, S., Lipton, S.A., Xu, H., 2014. Oligomeric Abeta-induced synaptic dysfunction in Alzheimer's disease. *Mol. Neurodegener.* 9, 48.
- Van Vickle, G.D., Esh, C.L., Kokjohn, T.A., Patton, R.L., Kalback, W.M., Luehrs, D.C., Beach, T.G., Newell, A.J., Lopera, F., Ghetti, B., Vidal, R., Castano, E.M., Roher, A.E., 2008. Presenilin-1 280Glu->Ala mutation alters C-terminal APP processing yielding longer abeta peptides: implications for Alzheimer's disease. *Mol. Med.* 14, 184–194.
- Varadarajan, S., Yatin, S., Kanski, J., Jahanshahi, F., Butterfield, D.A., 1999. Methionine residue 35 is important in amyloid beta-peptide-associated free radical oxidative stress. *Brain Res. Bull.* 50, 133–141.
- Venkataramani, V., Wirths, O., Budka, H., Hartig, W., Kovacs, G.G., Bayer, T.A., 2012. Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-beta in a fraction of amyloid-beta deposits in Alzheimer's disease without cross-reactivity with other protein aggregates. *J. Alzheimers Dis.* 29, 361–371.
- Viet, M.H., Nguyen, P.H., Ngo, S.T., Li, M.S., Derreumaux, P., 2013. Effect of the Totteri familial disease mutation (D7N) on the monomers and dimers of Abeta40 and Abeta42. *ACS Chem. Neurosci.* 4, 1446–1457.
- Villemagne, V.L., Pike, K.E., Chetelat, G., Ellis, K.A., Mulligan, R.S., Bourgeois, P., Ackermann, U., Jones, G., Szoek, C., Salvado, O., Martins, R., O'Keefe, G., Mathis, C.A., Klunk, W.E., Ames, D., Masters, C.L., Rowe, C.C., 2011. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. *Ann. Neurol.* 69, 181–192.
- Walsh, D.M., Hartley, D.M., Kusumoto, Y., Fezoui, Y., Condrón, M.M., Lomakin, A., Benedek, G.B., Selkoe, D.J., Teplow, D.B., 1999. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. *J. Biol. Chem.* 274, 25945–25952.
- Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., Selkoe, D.J., 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature* 416, 535–539.
- Wang, H.W., Pasternak, J.F., Kuo, H., Ristic, H., Lambert, M.P., Chromy, B., Viola, K.L., Klein, W.L., Stine, W.B., Krafft, G.A., Trommer, B.L., 2002. Soluble oligomers of beta amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. *Brain Res.* 924, 133–140.
- Wang, H., Sang, N., Zhang, C., Raghupathi, R., Tanzi, R.E., Saunders, A., 2015. Correction to cathepsin I mediates the degradation of novel APP C-terminal fragments. *Biochemistry* 54, 5781.
- Watson, D., Castano, E., Kokjohn, T.A., Kuo, Y.M., Lyubchenko, Y., Pinsky, D., Connolly Jr., E.S., Esh, C., Luehrs, D.C., Stine, W.B., Rowse, L.M., Emmerling, M.R., Roher, A.E., 2005. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. *Neurol. Res.* 27, 869–881.
- Watt, A.D., Perez, K.A., Rembach, A., Sherratt, N.A., Hung, L.V., Johansen, T., McLean, C.A., Kok, W.M., Hutton, C.A., Fodero-Tavoletti, M., Masters, C.L., Villemagne, V.L., Barnham, K.J., 2013. Oligomers, fact or artefact? SDS-PAGE induces dimerization of beta-amyloid in human brain samples. *Acta Neuropathol.* 125, 549–564.
- Watts, J.C., Condello, C., Stohr, J., Oehler, A., Lee, J., DeArmond, S.J., Lannfelt, L., Ingelsson, M., Giles, K., Prusiner, S.B., 2014. Serial propagation of distinct strains of Abeta prions from Alzheimer's disease patients. *Proc. Natl. Acad. Sci. U. S. A.* 111, 10323–10328.
- Willem, M., Tahirovic, S., Busche, M.A., Ovsepian, S.V., Chafai, M., Kootar, S., Hornburg, D., Evans, L.D., Moore, S., Daria, A., Hampel, H., Muller, V., Giudici, C., Nuscher, B., Wenninger-Weinzierl, A., Kremmer, E., Heneka, M.T., Thal, D.R., Giedraitis, V., Lannfelt, L., Muller, U., Livesey, F.J., Meissner, F., Herms, J., Konnerth, A., Marie, H., Haass, C., 2015. eta-Secretase processing of APP inhibits neuronal activity in the hippocampus. *Nature* 526, 443–447.
- Williams, T.L., Serpell, L.C., 2011. Membrane and surface interactions of Alzheimer's Abeta peptide—insights into the mechanism of cytotoxicity. *FEBS J.* 278, 3905–3917.
- Williams, S.M., Schulz, P., Sierks, M.R., 2016. Oligomeric alpha-synuclein and beta-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. *Eur. J. Neurosci.* 43, 3–16.
- Wirths, O., Erck, C., Martens, H., Harmeyer, A., Geumann, C., Jawhar, S., Kumar, S., Multhaup, G., Walter, J., Ingelsson, M., Degerman-Gunnarsson, M., Kalimo, H., Huitinga, I., Lannfelt, L., Bayer, T.A., 2010. Identification of low molecular weight pyroglutamate A[beta] oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. *J. Biol. Chem.* 285, 41517–41524.
- Wisniewski, T., Sigurdsson, E.M., 2010. Murine models of Alzheimer's disease and

- their use in developing immunotherapies. *Biochim. Biophys. Acta* 1802, 847–859.
- Wolfe, M.S., 2007. When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. *Talking Point on the role of presenilin mutations in Alzheimer disease*. *EMBO Rep.* 8, 136–140.
- Wolk, D.A., 2013. Amyloid imaging in atypical presentations of Alzheimer's disease. *Curr. Neurol. Neurosci. Rep.* 13, 412.
- Xu, X., 2009. Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain. *J. Alzheimers Dis.* 16, 211–224.
- Xu, F., Vitek, M.P., Colton, C.A., Previti, M.L., Gharkholonarehe, N., Davis, J., Van Nostrand, W.E., 2008. Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice. *J. Neurosci.* 28, 5312–5320.
- Yamaguchi, H., Nakazato, Y., Hirai, S., Shoji, M., Harigaya, Y., 1989. Electron micrograph of diffuse plaques. Initial stage of senile plaque formation in the Alzheimer brain. *Am. J. Pathol.* 135, 593–597.
- Yanagisawa, K., 2011. Pathological significance of ganglioside clusters in Alzheimer's disease. *J. Neurochem.* 116, 806–812.
- Yang, H., Fung, E.Y., Zubarev, A.R., Zubarev, R.A., 2009. Toward proteome-scale identification and quantification of isoaspartyl residues in biological samples. *J. Proteome Res.* 8, 4615–4621.
- Yang, X., Askarova, S., Lee, J.C., 2010. Membrane biophysics and mechanics in Alzheimer's disease. *Mol. Neurobiol.* 41, 138–148.
- Youssef, I., Florent-Bechard, S., Malaplate-Armand, C., Koziel, V., Bihain, B., Olivier, J.L., Leininger-Muller, B., Kriem, B., Oster, T., Pillot, T., 2008. N-truncated amyloid-beta oligomers induce learning impairment and neuronal apoptosis. *Neurobiol. Aging* 29, 1319–1333.
- Yu, X., Wang, Q., Pan, Q., Zhou, F., Zheng, J., 2013. Molecular interactions of Alzheimer amyloid-beta oligomers with neutral and negatively charged lipid bilayers. *Phys. Chem. Chem. Phys.* 15, 8878–8889.
- Zameer, A., Schulz, P., Wang, M.S., Sierks, M.R., 2006. Single chain Fv antibodies against the 25–35 Abeta fragment inhibit aggregation and toxicity of Abeta42. *Biochemistry* 45, 11532–11539.
- Zameer, A., Kasturirangan, S., Emadi, S., Nimmagadda, S.V., Sierks, M.R., 2008. Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. *J. Mol. Biol.* 384, 917–928.
- Zhang, Z., Song, M., Liu, X., Su, K.S., Duong, D.M., Seyfried, N.T., Cao, X., Cheng, L., Sun, Y.E., Ping, Y.S., Jia, J., Levey, A.J., Ye, K., 2015. Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's disease. *Nat. Commun.* 6, 8762.
- Zhao, G., Mao, G., Tan, J., Dong, Y., Cui, M.Z., Kim, S.H., Xu, X., 2004. Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. *J. Biol. Chem.* 279, 50647–50650.
- Zhao, J., Wang, P., Li, H., Gao, Z., 2015. Nitration of Y10 in Abeta1–40: is it a compensatory reaction against oxidative/nitrative stress and Abeta aggregation? *Chem. Res. Toxicol.* 28, 401–407.
- Zhou, C., Emadi, S., Sierks, M.R., Messer, A., 2004. A human single-chain Fv antibody blocks aberrant cellular effects of overexpressed alpha-synuclein. *Mol. Ther.* 10, 1023–1031.